Viewbix (VBIX) 10-K 18 Apr 17 2016 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2016	Jun. 30, 2016
Document And Entity Information
Entity Registrant Name	Emerald Medical Applications Corp.
Entity Central Index Key	797,542
Document Type	10-K
Document Period End Date	Dec. 31, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity a Well-known Seasoned Issuer	No
Entity a Voluntary Filer	No
Entity's Reporting Status Current	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float		$ 3,999,789
Entity Common Stock, Shares Outstanding	19,962,728
Trading Symbol	MRLA
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,016

Balance Sheets

Balance Sheets - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 4,486	$ 115,449
Other receivable	9,356	25,797
Total current assets	13,842	141,246
Restricted cash	11,925
Fixed assets, net of accumulated depreciation of $8,607 at December 31, 2016 and $6,536 at December 31, 2015	31,803	21,120
Total assets	57,570	162,366
Current liabilities:
Accounts payable and accrued liabilities	198,795	90,705
Accounts payable - related party	125,962	3,480
Employee payable	161,341	25,612
Accrued interest payable	32,768	19,285
Short term payable	29,743	119,974
Convertible note, net of discount of $305,417 at December 31, 2016 and $0 at December 31, 2015	409,588	29,719
Total current liabilities	958,197	288,775
Total liabilities	958,197	288,775
Stockholders' equity (deficit)
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; none issued.
Common stock, $0.0001 par value; 490,000,000 shares authorized; 19,962,728 and 15,325,889 shares issued and outstanding at December 31, 2016 and 2015, respectively.	1,994	1,533
Accumulated other comprehensive income	(19,337)	(19,337)
Additional paid-in capital	13,786,957	8,752,711
Accumulated deficit	(14,670,241)	(8,861,316)
Total stockholders' deficit	(900,627)	(126,409)
Total liabilities and stockholders' equity (deficit)	$ 57,570	$ 162,366

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Fixed assets, accumulated depreciation	$ 8,607	$ 6,536
Convertible note, discount	$ 305,417	$ 0
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	490,000,000	490,000,000
Common stock, shares issued	19,962,728	15,325,889
Common stock, shares outstanding	19,962,728	15,325,889

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Statement [Abstract]
Revenues
Expenses:
Research and development	(1,644,868)	(740,197)
General and administrative expenses	(3,749,867)	(7,303,292)	[1]
Total operating expenses	(5,394,735)	(8,043,489)
Loss from operations	(5,394,735)	(8,043,489)
Finance income (expense):
Finance expense	(414,190)	(34,751)
Loss on settlement of debt		(678,027)
Total finance income (expense):	(414,190)	(712,778)
Net loss	$ (5,808,925)	$ (8,756,267)
Basic and diluted (net loss per share)	$ (0.31)	$ (0.81)
Weighted average shares outstanding - basic and diluted	18,966,032	10,872,526
[1]	Following the closing of the reverse merger, the $490,000 loan from Emerald Medical Applications Corp. to Emerald Medical Applications Ltd. was rendered an intercompany loan and as such was written off.

Statements of Comprehensive Inc

Statements of Comprehensive Income (Loss) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Statement [Abstract]
Net loss	$ (5,808,925)	$ (8,756,267)
Change in unrealized foreign currency translation gain (loss)		(28,269)
Total comprehensive income (loss)	$ (5,808,925)	$ (8,784,536)

Statements of Cash Flows

Statements of Cash Flows - USD ($)		12 Months Ended
		Dec. 31, 2016	Dec. 31, 2015
Operating Activities:
Net (loss)		$ (5,808,925)	$ (8,756,267)
Depreciation expense		12,422	6,494
Amortization of debt discount		369,588	9,555
Shares issued for services		2,263,304	885,984
Warrants issued for services			5,343,088
Loss on settlement of debt			678,027
Employee option expense		2,028,803	397,547
Adjustments to reconcile net (loss) to net cash (used in) operating activities:
Increase in accounts payable and accrued liabilities		168,090	109,176
Increase in employees payable		75,729	24,913
Decrease in amounts due from related party		122,482	18,739
Increase in other payable		(119,950)
Decrease in accrued interest		13,483
Increase in other receivables		16,441	(19,079)
Net cash used in operating activities		(858,533)	(1,301,823)
Investing Activities:
Increase in restricted cash		(11,925)
Purchase of fixed assets		(23,105)	(26,224)
Effect of reverse merger			467,380
Net cash provided by investing activities		(35,030)	441,156
Financing Activities:
Proceeds from sale of common stock and warrants (net of issuance expenses)		47,600	380,000
Issuance of short-term convertible notes		735,000	609,974
Net cash provided by financing activities		782,600	989,974
Effect of exchange rates on cash and cash equivalents			(28,269)
Net increase (decrease) in cash		(110,963)	101,038
Cash and cash equivalents - beginning of period		115,449	14,411
Cash and cash equivalents - end of period		4,486	115,449
Non-cash transactions
Shares issued for reverse merger			547
Write of loan(*)	[1]		490,000
Debt settled with stock			91,687
Cashless Exercise of Warrants		192
Extinguishment of a derivative			$ 20,532
[1]	Following the closing of the reverse merger, the $490,000 loan from Emerald Medical Applications Corp. to Emerald Medical Applications Ltd. was rendered an intercompany loan and as such was written off.

Statement of Changes in Stockho

Statement of Changes in Stockholders’ Equity (Deficit) - USD ($)	Common Stock [Member]	Additional Paid-In Capital [Member]	Stock Payable [Member]	Other Comprehensive Income [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2014	$ 744	$ (744)		$ 8,932	$ (105,049)	$ (96,117)
Balance, shares at Dec. 31, 2014	7,438,141
Common stock and warrants issued for cash	$ 125	459,875	(80,000)			380,000
Common stock and warrants issued for cash, shares	1,252,500
Debt converted into shares	$ 27	769,686				769,713
Debt converted into shares, shares	274,719
Shares issued for services	$ 88	885,896				885,984
Shares issued for services, shares	885,984
Class B and C warrants for services		5,343,088				5,343,088
ESOP options		397,547				397,547
Effect of reverse merger	$ 547	876,833	80,000			957,380
Effect of reverse merger, shares	5,474,545
Other comprehensive income				(28,269)		(28,269)
Extinguishment on derivative		20,532				20,532
Cashless exercise of warrants
Net loss for the year					(8,756,267)	(8,756,267)
Balance at Dec. 31, 2015	$ 1,533	8,752,711		(19,337)	(8,861,316)	(126,409)
Balance, shares at Dec. 31, 2015	15,325,889
Common stock and warrants issued for cash	$ 12	47,588				47,600
Common stock and warrants issued for cash, shares	119,000
Shares issued for services	$ 256	2,263,046				2,263,302
Shares issued for services, shares	2,558,017
ESOP options		2,028,805				2,028,805
Other comprehensive income
Cashless exercise of warrants	$ 193	(193)				192
Cashless exercise of warrants, shares	1,928,572
Issuance of convertible notes with beneficial conversion feature		695,000				695,000
Net loss for the year					(5,808,925)	(5,808,925)
Balance at Dec. 31, 2016	$ 1,994	$ 13,786,957		$ (19,337)	$ (14,670,241)	$ (900,627)
Balance, shares at Dec. 31, 2016	19,931,478

The Company and Significant Acc

The Company and Significant Accounting Policies	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
The Company and Significant Accounting Policies	Note 1. The Company and Significant Accounting Policies. Organizational Background: The Company’s predecessor, Zaxis International Inc. (“Zaxis”) was incorporated in the State of Ohio in 1989. On August 25, 1995, Zaxis merged with a subsidiary of The InFerGene Company, a Delaware corporation, which entity changed its name to Zaxis International Inc. and the Company was reincoirporated in Delaware as Zaxis. On December 30, 2014, Zaxis entered into a non-binding Memorandum of Understanding (“MOU”) with Emerald Medical Applications Ltd., which was then a private limited liability company incorporated under the laws of the State of Israel (“Emerald Ltd”). On March 16, 2015, Zaxis and Emerald Ltd executed the Share Exchange Agreement. Pursuant to the terms of the Share Exchange Agreement, the Company agreed to issue to the holders of Emerald Ltd’s ordinary shares a total of 5,474,545 shares of the Company’s common stock representing approximately 45% of the Company’s outstanding common stock upon the closing. In addition, the Share Exchange Agreement also provided that the Registrant will issue to Lior Wayn, Emerald Ltd’s CEO and founder, warrants exercisable to acquire 2,700,000 shares of common stock, in three equal tranches of 900,000 shares, at an exercise price of $0.0001 per share, which warrants vested based upon the Company meeting the certain milestones set forth in the Share Exchange Agreement and would represent an additional 21% of the Company’s total outstanding common stock after exercise. On July 14, 2015, the closing of the Share Exchange Agreement was held and the Registrant issued 5,474,545 shares of its common stock to the holders of Emerald Ltd’s ordinary shares in exchange for 100% of Emerald Ltd and, as a result, Emerald Ltd became a wholly owned subsidiary of the Company as of July 14, 2015, following which the Company changed its name to Emerald Medical Applications Corp. The transaction between the Company and Emerald Ltd. was accounted for as a reverse recapitalization. As the shareholders of Emerald Ltd. received the largest ownership interest in the Company, based upon the 5,474,545 shares issued at the closing, the 2.7 warrants exercisable at par and most significantly, the fact that the Share Exchange Agreement expressly provided that a majority of the Company’s board of directors could be appointed by Emerald Ltd., Emerald Ltd. was determined to be the “accounting acquirer” in the reverse recapitalization. As a result, the historical financial statements of the Company were replaced with the historical financial statements of Emerald Ltd. The Company and its subsidiary Emerald Ltd., are collectively referred to as the “Company”. Emerald Medical Applications Ltd (“Emerald”), a wholly-owned subsidiary of the Registrant effective July 14, 2015, was organized as a privately-owned company under the laws of the State of Israel on February 17, 2010. Emerald is a digital health startup company engaged in the development, sale and service of imaging solutions utilizing its proprietary DermaCompare software that it developed for use in derma imaging and analytics (“DermaCompare”). Emerald believes that its proprietary DermaCompare software represents an advancement in skin cancer screening that should enable physicians to more readily identify and monitor changes in their patients’ skin characteristics. Emerald’s DermaCompare solution allows dermatologists and other medical care professionals, using a set of 25 total body photography (“TBP”), to capture sets of skin lesion images with, among other devices, digital cameras, camera-equipped smart phones or tablets. These images are then transmitted online and are remotely analyzed by professionals using our DermaCompare software. Our sales and marketing plan, which has already commenced, is to sell licenses for our DermaCompare imaging software to: NHSs, HMOs, health insurance companies, hospitals and medical clinics through distributers, health care channel partners or directly through independent salespersons and/or web purchase to dermatologists and other physicians (GPs) that we expect to purchase licenses based on the number of potential numbers of patients. Basis of Presentation: The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. The Company has not established any source of revenue to cover its operating costs, and as such, has incurred an operating loss since inception. Further, as of December 31, 2016, the cash resources of the Company were insufficient to meet its current business plan, and the Company had negative working capital. These and other factors raise substantial doubt about the Company’s ability to continue as a going concern. The Company’s ability to continue operating as a “going concern” is dependent on several factors, among them is the ability to raise sufficient additional funding. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern. Significant Accounting Policies Use of Estimates: The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from the estimates. Cash and Cash Equivalents: For financial statement presentation purposes, the Company considers those short-term, highly liquid investments with original maturities of three months or less to be cash or cash equivalents. There were no cash equivalents as of December 31, 2016 and December 31, 2015. Other Receivables The Company treats VAT refunds claimed resulting from excess VAT paid over VAT received as other receivables, amount shown as other receivables as of December 31, 2016 was $ 8,234. Currency Translation and other Comprehensive Income The functional currency of the Emerald Application Corp. is the U.S dollar (“dollar”) since the dollar is the currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future. Transactions and balances denominated in dollars are presented at their original amounts. Transactions and balances denominated in foreign currencies have been re-measured to dollars in accordance with the provisions of ASC 830-10, “Foreign Currency Translation”. All transaction gains and losses from re-measurement of monetary balance sheet items denominated in non-dollar currencies are reflected in the statement of operations as financial income or expenses, as appropriate. Prior to January 1, 2016, Emerald Medial Application Ltd.’s functional currency was the New Israeli Shekel (“NIS”). Translation gains and losses from the application of the U.S. dollar as the reporting currency while the NIS was the functional currency are included as part of cumulative currency translation adjustment, which is reported as a component of shareholders’ equity under accumulated other comprehensive loss. Emerald Medial Application Ltd, re-assessed its functional currency and determined as at January 1, 2016, its functional currency changed from NIS to the U.S. dollar based on management’s analysis of changes in the primary economic environment in which the Company operates. The change in functional currency is accounted for prospectively from January 1, 2016. fixed assets: New property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally 6 years. Expenditures for renewals and betterments are capitalized. Expenditures for minor items, repairs and maintenance are charged to operations as incurred. Gain or loss upon sale or retirement due to obsolescence is reflected in the operating results in the period the event takes place. Accounting For Obligations And Instruments Potentially To Be Settled In The Company’s Own Stock: We account for obligations and instruments potentially to be settled in the Company’s stock in accordance with FASB ASC 815, Accounting for Derivative Financial Instruments. This guidance addresses the initial balance sheet classification and measurement of contracts that are indexed to, and potentially settled in, the Company’s own stock. Fair Value of Financial Instruments: FASB ASC 825, “Financial Instruments,” requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value. FASB ASC 825 defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. At December 31, 2015 and 2014, the carrying value of certain financial instruments (cash and cash equivalents, accounts payable and accrued expenses.) approximates fair value due to the short-term nature of the instruments or interest rates, which are comparable with current rates. Accounting For Convertible Debt Instruments We account for convertible debt instruments, which do not meet the definition of a derivative financial instrument per FASB ASC 815, Accounting for Derivative Financial Instruments, in accordance with FASB ASC 470-20, Debt with Conversion and Other Options. This guidance addresses the allocation of proceeds from the issuance of convertible debt into its equity and debt components. Discount on the debt component resulting from allocation of proceeds to the equity component is amortized in the profit and loss statement as finance expense. Allocation of proceeds into equity and debt components of convertible notes issued together with other detachable financial instruments is performed in relation to the proceeds allocated to the convertible notes based on the relative fair value of such convertible notes and the other detachable financial instruments issued. Share-based compensation The Company applies ASC 718-10, “Share-Based Payment,” which requires the measurement and recognition of compensation expenses for all share-based payment awards made to employees and directors (including employee stock options under the Company’s stock plans) based on estimated fair values. ASC 718-10 requires companies to estimate the fair value of equity-based payment awards on the date of grant. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company’s statement of operations. The Company recognizes compensation expenses for the value of non-employee awards based on the straight-line method over the requisite service period of each award, net of estimated forfeitures. The Company estimates the fair value of stock options granted as equity awards using a Black-Scholes options pricing model. The option-pricing model requires a number of assumptions, of which the most significant are share price, expected volatility and the expected option term (the time from the grant date until the options are exercised or expire). Expected volatility is estimated based on volatility of similar companies in the technology sector. The Company has historically not paid dividends and has no foreseeable plans to issue dividends. The risk-free interest rate is based on the yield from governmental zero-coupon bonds with an equivalent term. The expected option term is calculated for options granted to employees and directors using the “simplified” method. Grants to non-employees are based on the contractual term. Changes in the determination of each of the inputs can affect the fair value of the options granted and the results of operations of the Company. Fair Value Measurements: The Company adopted the FASB standard related to fair value measurement at inception. The standard defines fair value, establishes a framework for measuring fair value and expands disclosure of fair value measurements. The standard applies under other accounting pronouncements that require or permit fair value measurements and, accordingly, does not require any new fair value measurements. The standard clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the standard established a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows. Level 1. Observable inputs such as quoted prices in active markets; Earnings per Common Share We compute net income (loss) per share in accordance with ASC 260, Earning per Share. ASC 260 requires presentation of both basic and diluted earnings per share (EPS) on the face of the income statement. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing, Diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive. All per share disclosures retroactively reflect shares outstanding or issuable as though the reverse split had occurred January 1, 2012. The weighted average number of Ordinary Shares outstanding has been retroactively restated for the equivalent number of shares received by the accounting acquirer as a result of the reverse recapitalization as if these shares had been outstanding as of the beginning of the earliest period presented Research and development expenses, net: Research and development expenses are charged to the statement of operations as incurred. Grants for funding of approved research and development projects are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred and applied as a deduction from the research and development expenses. Income Taxes: We have adopted FASB ASC 740, Accounting for Income Taxes. Pursuant to ASC 740, we are required to compute tax asset benefits for net operating losses carried forward. The potential benefits of net operating losses have not been recognized in these financial statements because the Company cannot be assured it is more likely than not it will utilize the net operating losses carried forward in future years. We must make certain estimates and judgments in determining income tax expense for financial statement purposes. These estimates and judgments occur in the calculation of certain tax assets and liabilities, which arise from differences in the timing of recognition of revenue and expense for tax and financial statement purposes. Deferred tax assets and liabilities are determined based on the differences between financial reporting and the tax basis of assets and liabilities using the tax rates and laws in effect when the differences are expected to reverse. ASC 740 provides for the recognition of deferred tax assets if realization of such assets is more likely than not to occur. Realization of our net deferred tax assets is dependent upon our generating sufficient taxable income in future years in appropriate tax jurisdictions to realize benefit from the reversal of temporary differences and from net operating loss, or NOL, carryforwards. We have determined it more likely than not that these timing differences will not materialize and have provided a valuation allowance against substantially all of our net deferred tax asset. Management will continue to evaluate the realizability of the deferred tax asset and its related valuation allowance. If our assessment of the deferred tax assets or the corresponding valuation allowance were to change, we would record the related adjustment to income during the period in which we make the determination. Our tax rate may also vary based on our results and the mix of income or loss in domestic and foreign tax jurisdictions in which we operate. In addition, the calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax regulations. We recognize liabilities for anticipated tax audit issues in the U.S. and other tax jurisdictions based on our estimate of whether, and to the extent to which, additional taxes will be due. If we ultimately determine that payment of these amounts is unnecessary, we will reverse the liability and recognize a tax benefit during the period in which we determine that the liability is no longer necessary. We will record an additional charge in our provision for taxes in the period in which we determine that the recorded tax liability is less than we expect the ultimate assessment to be. ASC 740 which requires recognition of estimated income taxes payable or refundable on income tax returns for the current year and for the estimated future tax effect attributable to temporary differences and carry-forwards. Measurement of deferred income tax is based on enacted tax laws including tax rates, with the measurement of deferred income tax assets being reduced by available tax benefits not expected to be realized. Uncertain Tax Positions: When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of FASB ASC 740-10, Accounting for Uncertain Income Tax Positions, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above should be reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination. Recent Accounting Pronouncements In September 2015, the FASB issued ASU No. 2015-16, Business Combinations (Topic 805) (“ASU 2015-16”). Topic 805 requires that an acquirer retrospectively adjust provisional amounts recognized in a business combination, during the measurement period. To simplify the accounting for adjustments made to provisional amounts, the amendments in the Update require that the acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amount is determined. The acquirer is required to also record, in the same period’s financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the provisional amounts, calculated as if the accounting had been completed at the acquisition date. In addition an entity is required to present separately on the face of the income statement or disclose in the notes to the financial statements the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment to the provisional amounts had been recognized as of the acquisition date. ASU 2015-16 is effective for fiscal years beginning December 15, 2015. The adoption of ASU 2015-016 is not expected to have a material effect on the Company’s consolidated financial statements. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date (“ASU 2015-14”). The amendment in this ASU defers the effective date of ASU No. 2014-09 for all entities for one year. Public business entities, certain not-for-profit entities, and certain employee benefit plans should apply the guidance in ASU 2014-09 to annual reporting periods beginning December 15, 2017, including interim reporting periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 31, 2016, including interim reporting periods with that reporting period. In April 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2015-03, Interest-Imputation of Interest (Subtopic 835-30) (“ASU 2015-03”), which changes the presentation of debt issuance costs in financial statements. ASU 2015-03 requires an entity to present such costs in the balance sheet as a direct deduction from the related debt liability rather than as an asset. Amortization of the costs will continue to be reported as interest expense. It is effective for annual reporting periods beginning after December 15, 2016. Early adoption is permitted. The new guidance will be applied retrospectively to each prior period presented. The Company is currently in the process of evaluating the impact of adoption of ASU 2015-03 on its balance sheets. In January 2016, the FASB issued ASU 2016-01 “Recognition and Measurement of Financial Assets and Financial Liabilities”, which provides targeted improvements to the recognition, measurement, presentation and disclosure of financial assets and financial liabilities. Specific accounting areas addressed include, equity investments, financial liabilities reported under the fair value option and valuation allowance assessment resulting from unrealized losses on available-for-sale securities. The standard also changes certain presentation and disclosure requirements for financial instruments. This ASU is effective for the Company in its first quarter of fiscal year 2019. Early adoption, with certain exceptions, is not permitted. The Company does not expect that the adoption of this standard will have a significant impact on the financial position or results of operations. In March 2016, the FASB issued Accounting Standards Update No. 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting (“ASU 2016-09”), which simplifies certain provisions associated with the accounting for stock compensation. Among other things, ASU 2016-09 requires companies to record excess tax benefits and tax deficiencies as income tax benefit or expense in the statement of income and eliminates the requirement to reclassify cash flows related to excess tax benefits from operating activities to financing activities in the statement of cash flows. ASU 2016-09 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016, with early adoption permitted. The Company is currently reviewing and evaluating this guidance and its impact on its consolidated financial statements.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2016
Equity [Abstract]
Stockholders' Equity	Note 2. Stockholders’ Equity. On January 8, 2015, the Board of Directors and the majority consenting stockholders of the Company executed a Joint Written Consent in accordance with the provisions of Section 242 of the Delaware General Corporation Law, to increase the authorized capital stock of the Company from 100,000,000 shares of common stock to 490,000,000 shares of common stock (the “Joint Written Consent”). All other provisions of the Company’s capital stock remained unchanged. Also, on that same date, the Company’s Board of Directors and majority consenting stockholders authorized a reverse split of common stock at the ratio of 1:4. The effective date of the reverse split was March 20, 2015, the date that FINRA approved implementation of the reverse recapitalization. Except as otherwise noted, all share, option and warrant numbers have been restated to give retroactive effect to this reverse split. All per share disclosures retroactively reflect shares outstanding or issuable as though the reverse split had occurred at the beginning of the earliest period presented. January 1, 2012 The number of ordinary shares outstanding has been retroactively restated for the equivalent number of shares received by the accounting acquirer as a result of the reverse recapitalization as if these ordinary shares had been outstanding as of the beginning of the earliest period presented Recent Issuances of Common Stock Between January 15, 2015 and March 15, 2015, the Company sold a total of 2,052,000 units for cash consideration of $780,000 at a price of $0.40 (the “Units”), each unit comprised of one share of common stock and one Class A warrant exercisable at $0.80 per share with a term 24 month. These units were issued as stock payable and the cash from sale of units was not received for the sale of stock pre-reverse merger Between April 1, 2015 and June 29, 2015, the Company sold a total of 1,012,500 units for cash consideration of $405,000 at a price of $0.40 (the “Units”), each unit comprised of one share of common stock and one Class A warrant exercisable at $0.80 per share with a term 24 month. These units were issued as stock payable and the cash from sale of units was not received for the sale of stock pre-reverse merger. On July 21, 2015 the Company sold a total of 140,000 units for cash consideration of $15,000 at price of $0.107 (the “Units”), each unit comprised of one share of common stock and one Class A warrant exercisable at $0.80 per share with a term 24 month. These units were issued as stock payable and the cash from sale of units was not received for the sale of stock pre-reverse merger. Between July 1, 2015 and September 30, 2015 the Company sold a total of 862,500 units for cash consideration of $345,000 at price of $0.40 (the “Units”), each unit comprised of one share of common stock and one Class A warrant exercisable at $0.80 per share with a term 24 month. Of these units $65,000 were issued as stock payable and the cash from sale of units was not received for the sale of stock pre-reverse merger and $280,000 cash was received subsequent to Closing of the reverse merger. On July 31, 2015 and July 30, 2015 the Company issued 517,900 shares to one service provider, for financial and marketing consultant, and a total of 100,000 shares to two service providers, respectively, for services valued at a total value of $617,900, arrived at using the stock price on date of grant of $1.00 per Nasdaq.com. On July 16, 2015 five Emerald debt holders in amount of $87,910 converted their debt into 274,719 units at a conversion price of $0.32 per unit, each unit comprised of one share of common stock and one Class A warrant exercisable at $0.80 per share with a term 24 month. The Loss on Settlement of Debt recorded is $678,027. On July 14, 2015 the Company issued Emerald’s CEO and founder, Lior Wayn, 5,474,545 shares as per the share purchase agreement valued at $877,380, valued on the date of grant for the price of common stock. On July 16, 2015 consultants were issued 2,500,000 Class B Warrants exercisable for a two-year period to acquire one (1) share of Common Stock at a price of $0.40 per share; The fair value of these warrants is $2,199,507. The warrants were valued using the Black-Scholes model with volatility of 182% and discount rate of 0.67%. The Class B warrants are fully vested and were accordingly included in expenses as stock based compensation. On July 16, 2015 consultants were issued 2,536,247 Class C Warrants exercisable for a 90 day period, commencing 90 days after the effective date of this Registration Statementat an exercise price of $0.40 to acquire one (1) share of Common Stock and one (1) Class A Warrant at an exercise price of $0.80. The fair value of these warrants is $3,143,581. The warrants were valued using the Black-Scholes model with volatility of 182% and discount rate of 0.67%. The Class C warrants are fully vested and were accordingly included in expenses as stock based compensation. On November 17, 2015, the Company sold 250,000 units for cash consideration of $100,000 at price of $0.40 (the “Units”), each unit comprised of one share of common stock and one Class A warrant exercisable at $0.80 per share with a term 24 month. The relative fair value of the stock with embedded warrants was $41,304 for the common stock and $58,696 for the class A warrants. The warrants were valued using the Black-Scholes model with volatility of 149% and a discount rate of 0.50%. Between November 5, 2015 and November 16, 2015 the Company issued 268,084 shares to three service providers and for services valued at a total value of $268,084, arrived at using the stock price on date of grant of $1.00 per Nasdaq.com. On January 26, 2016 and March 17, 2016, the Company issued 125,000 common shares to one service provider and 50,000 common shares to two service providers, respectively, for services valued at a total value of $251,250, arrived at using the stock price on date of grant of $1.75 and $0.65, respectively, per Nasdaq.com. On February 18, 2016, the Company issued 1,195,000 shares to three acting directors, for services valued at a total value of $1,194,403, arrived at using the stock price on date of grant of $1.00 per Nasdaq.com. On January 26, 2016, consultants that were previously issued 2,500,000 Class B Warrants exercisable for a two-year period to acquire one (1) share of Common Stock at a price of $0.40 per share, exercised the warrants on a cashless basis resulting in 1,928,572 shares issued with no additional related expense booked. On March 24, 2016, a convertible note payable and warrants where was issued to GoldMed Ltd for a consideration of $75,000 The warrants and the beneficial conversion feature were valued at $75,000, which resulted in a $75,000 discount recorded as a reduction of debt and an increase to additional paid in capital. The discount is amortized in finance expense over the term of the note. On April 11, 2016, a convertible note payable and warrants was issued to Maz Partner. The warrants and the e beneficial conversion feature were valued at $80,000, which resulted in a $80,000 discount recorded as a reduction of debt and an increase to additional paid in capital. The discount is amortized in finance expense over the term of the note. On May 5, 2016, the Company issued 150,000 shares to one service provider for services valued at a total value of $105,000, arrived at using the stock price on date of grant of $0.7, per Nasdaq.com. On May 10, 2016, the Company issued 41,667 shares to one service provider for services valued at a total value of $29,584, arrived at using the stock price on date of grant of $0.71, per Nasdaq.com. On May 18, 2016, the Company issued 150,000 shares to one service provider for services valued at a total value of $102,000, arrived at using the stock price on date of grant of $0.68, per Nasdaq.com. On June 28, 2016, the Company issued 175,000 shares to three service providers for services valued at a total value of $122,500, arrived at using the stock price on date of grant of $0.7, per Nasdaq.com. On June 30, 2016, the Company issued 333,333 shares to one service provider for services valued at a total value of $226,666, arrived at using the stock price on date of grant of $0.68, per Nasdaq.com. On June 6, 2016, a convertible note payable and warrants was issued to Alpha Capital. The warrants and the beneficial conversion feature were valued at $440,000, which resulted in a $440,000 discount recorded as a reduction of debt and an increase to additional paid in capital. The discount is amortized in finance expense over the term of the note. On June 30, 2016, a convertible note payable and warrants was issued to Ilan Malka. The warrants and the embedded beneficial conversion feature were valued at $40,000, which resulted in a $40,000 discount recorded as a reduction of debt and an increase to additional paid in capital. The discount is amortized in finance expense over the term of the note. On July 7, 2016, a convertible note payable and warrants was issued to Firstfire Global Opportunities Fund LTC. The warrants and the beneficial conversion feature were valued at $100,000, which resulted in a $100,000 discount recorded as a reduction of debt and an increase to additional paid in capital. The discount is amortized in finance expense over the term of the note. On July 1, 2016, the Company issued 300,000 shares to one service provider for service valued at a total value of $213,000 arrived at using the stock price on date of grant of $0.71, per Nasdaq.com. On July 1, 2016, the Company issued 6,767 shares to one service provider for service valued at a total value of $3,587 arrived at using the stock price on date of grant of $0.53, per Nasdaq.com. On August 4, 2016, the Company issued 31,250 shares to one service provider for service valued at a total value of $15,313, arrived at using the stock price on date of grant of $0.49, per Nasdaq.com. On November 10, 2016, the Company issued 119,000 units to Guy Shalom in total amount of $47,600. Each unit consist 119,000 warrants exercisable for a two-year period in exercise price of $0.8 and 119,000 common shares. The following table summarizes information of outstanding warrants as of December 31, 2016: Warrants Warrant Term Exercise Price Exercisable Investors - Class A Warrants (1) 5,918,719 2 years $ 0.80 5,918,719 Investors - Class B Warrants (2) 1,350,000 2 years $ 0.40 1,350,000 Investors - Class C Warrants (3) 5,072,492 (3 ) $ (3 ) 5,536,246 Alimi Ahmed - Class E Warrants (4) 900,000 (4 ) $ 0.0001 900,000 The Class A Warrants were issued in connection with a private placement in reliance upon Regulation S, pursuant to which the Registrant sold a total of 5,918,719 units at a price of $0.40 per unit (the “Units”), each Unit comprised of one Share and one Class A Warrant exercisable at $0.80 per share with a term 24 months. While all of the Class A Warrants are exercisable within 60 days, in fact, none of these warrants will be exercised for the foreseeable future, based upon the exercise price of $0.80 per Share. (2) The Class B Warrants were issued to consultants for bona fide services to the Company and are exercise, on a cashless basis at a price of $0.40 per Share for a period of two years. (3) The Class C Unit Warrants were issued to consultants for bona fide services to the Company, and each Unit is exercisable at a price of $0.40 to purchase one Share of Common Stock and one Class A Warrant which, in turn, is exercisable to purchase one additional Share at a price of $0.80. The Class C Unit Warrants expire ninety (90) days after the effective date of this Registration Statement. (4) A total of 2,700,000 Class E Warrants were issued by the Registrant to Lior Wayn pursuant to the terms of the Share Exchange Agreement and were exercisable in three equal tranches of 900,000 Shares each (the “Tranches”) at an exercise price of $0.0001 per Share, subject to and within 45 days of the Registrant achieving the milestones defined in the Share Exchange Agreement On December 16, 2016, the Company filed a Form 8-K reporting the termination of Lior Way’s employment agreements with the Company and Emerald Ltd., and his removal as an executive officer and director. After the year-ended December 31, 2016, Mr. Wayn transferred, sold and assigned his 5,212,878 shares of the Company’s common stock and 900,000 Class E Warrants that were fully-vested to an entity controlled by Mr. Alimi Ahmed, then a member of the Company’s Board of Directors. This transaction was reported in the Company’s Form 8-K filed with the SEC on January 27, 2017. Effective as of December 31, 2016, the remaining 1,800,000 Class E Warrants that had been issued to Mr. Wayn Warrants were canceled. Sale of Unregistered Securities During the last two years, the Registrant issued the following restricted shares which were not registered under the Act On June 18, 2015 and July 21, 2015, after the Company ceased to be a shell company, the Company issued and sold unregistered securities, as set forth in the table below, in private offering of a total of 2,925,000 units at a price of $0.40. Each Unit consisted of one Share and one Class A Warrant exercisable to purchase one additional Share of Common Stock at a price of $0.80 (the “Units”). The sales were made without registration under the Act in reliance upon the exemptions provided in Section 4(2) of the Act and Reg S. Name of Subscriber Bases for Issuance Date of Issuance Price Per Unit Shares Issued Short Trade Ltd (1) Subscription Agreement 06/18/2015 $ 0.40 625,000 Prop Trade Ltd (2) Subscription Agreement 06/18/2015 $ 0.40 375,000 Dr. Ben Zion Weiner Subscription Agreement 06/18/2015 $ 0.40 125,000 RP Holdings (1992) Ltd. (3) Subscription Agreement 06/18/2015 $ 0.40 125,000 Dr. Tank Siak Khim Subscription Agreement 06/18/2015 $ 0.40 250,000 Yoel Yogev Subscription Agreement 06/18/2015 $ 0.40 200,000 Universal Link Ltd (4) Subscription Agreement 06/18/2015 $ 0.40 175,000 Avigdor Hakmon Subscription Agreement 06/18/2015 $ 0.40 62,500 Dr. Shmuel Pasternak Subscription Agreement 06/18/2015 $ 0.40 62,500 Liat Sidi Subscription Agreement 07/21/2015 $ 0.40 25,000 Tzvi Aharonson Subscription Agreement 07/21/2015 $ 0.40 137,500 Estory Giloz Ran Subscription Agreement 07/21/2015 $ 0.40 312,500 Malca Maimon Subscription Agreement 07/21/2015 $ 0.40 87,500 Ohad Cohen Subscription Agreement 07/21/2015 $ 0.40 150,000 Nissim Simhon Subscription Agreement 07/21/2015 $ 0.40 50,000 NE Solution Ltd (5) Subscription Agreement 07/21/2015 $ 0.40 162,500 Total $ 1,169,961 2,925,000 (1) Short Trade Ltd is controlled by Mr. Shlomo Noyman, a resident of Israel. (2) Prop Trade Ltd is controlled by Mr. Andrew Philip Dings, a resident of Singapore. (3) RP Holdings (1992) Ltd. is controlled by Mr. Rubin Zimerman, a resident of Israel. (4) Universal Link Ltd is controlled by Mr. Ahmad Alimi, a resident of Israel. (5) NE Solution Ltd is controlled by Mr. Lee Yang Tong, a resident of Singapore. In July 2015, the persons listed in the table below, each a lender to Emerald on or before November 2014, converted their debt owed by Emerald into Units, each consisting of one restricted Share and one Class A Warrant, at a conversion price of $0.32. Each of the lenders was a resident of Israel and the issuance was without registration under the Act in reliance upon the exemptions provided in Section 4(2) of the Act and Reg S. Name of Note Holder Bases of Issuance Debt Converted Shares Issued David Masasa Conversion of Debt $ 8,788 27,463 Liron Carmel Conversion of Debt $ 19,521 61,003 Yoseph Cohen Conversion of Debt $ 15,632 48,850 Tzvi Aharonson Conversion of Debt $ 43,969 137,403 Total $ 87,910 274,719 On July 21, 2015, the Registrant issued 140,000 restricted Shares to Shira Brand Shiffer, a resident of Israel, at a price of $0.107 per Share, with no warrants attached. The issuance to Shira Brand Shiffer, without registration under the Act, was made in reliance upon Section 4(2) of the Act and Reg S. On July 16, 2015, the Registrant issued 517,900 restricted shares of Common Stock to Meyda Consulting Ltd, an entity organized under the laws of Israel controlled by Eliyahu Kirstein, a resident of Israel. The issuance of these shares was in consideration for services and was made without registration under the Act in reliance upon the exemptions provided in Section 4(2) of the Act and Reg S. On July 16, 2015, the Registrant issued Class B Warrants and Class C Unit Warrants to the following entities for bona fide services to the Registrant. The issuances of these Warrants were in consideration for services and was made without registration under the Act in reliance upon the exemptions provided in Section 4(2) of the Act and Reg S. Basis of Issuance Class B Warrant Issued Class C Unit Warrants Issued Total Warrants Issued Yaad Consulting Ltd. (1) Services 625,000 $ 634,063 1,259,063 LA Pure Capital Ltd. (2) Services 375,000 $ 380,467 755,467 Amir Uziel Economic Consultant Ltd. (3) Services 625,000 $ 634,061 1,259,061 Capitalink Ltd. (4) Services 625,000 $ 634,061 1,259,061 (1) The control person of Yaad Consulting Ltd is Itschak Shrem, a resident of Israel. During November 2015, the Registrant issued and sold unregistered Shares as set forth on the table below: Name of Issuee Date of Issuance Number of Shares Consideration Bases for Issuance Shirat Hahayim 11/17/2015 250,000 $0.40 per share Subscription Agreement (1) Lyons Capital LLC. (2) 11/05/2015 250,000 Valued at $1.00 per share Services David Treves 11/16/2015 12,334 Valued at $1.00 per share Services Pnina Rosenblum 11/09/2015 5,750 Valued at $1.00 per share Services Total Shares Issued 518,084 (1) The issuance was pursuant to a Unit Subscription Agreement each consisting of 1 Share and 1 Class A Warrant exercisable for a period of 24 months to purchase 1 additional Share at $0.80. The issuance and sale of Shares to Shirat Hahayim and Pnina Rosenbluem, residents of the State of Israel, and David Treves, resident of Australia, without registration under the Act, was made in reliance upon the exemptions provided in Section 4(2) of the Act and and Regulation S promulgated by the United States Securities and Exchange Commission (the “SEC”) under the Act. The issuance of Shares to Lyons Capital LLC, without registration under the Act, was in reliance upon Section 4(2) and Regulation D promulgated by the SEC under the Act. During 2016, the Registrant issued and sold common Shares as set forth on the table below: Name of Issuee Date of Issuance Number of Shares Consideration Bases for Issuance Yair Fudim 02/18/2016 482,000 Valued at $0.9995 per share Services Estery Giloz Ran 02/18/2016 482,000 Valued at $0.9995 per share Services Baruch Kfir 02/18/2016 231,000 Valued at $0.9995 per share Services Legend Securities Inc 03/17/2016 50,000 Valued at $0.65per share Services JFS Investments PR LLC 01/26/2016 125,000 Valued at $1.75 per share Services Garden state securities Inc 05/04/2016 150,000 Valued at $0.70 per share Services JFS Investments PR LLC 05/10/2016 41,667 Valued at $0.71 per share Services Kodiak Capital Group LLc 05/18/2016 150,000 Valued at $0.68 per share Services Alpha Capital Anstalt 06/26/2016 125,000 Valued at $0.70 per share Services Legend Securities Inc 06/28/2016 50,000 Valued at $0.70 per share Services JFS Investments PR LLC 06/30/2016 333,333 Valued at $0.68 per share Services VAR Growth Corporation 07/01/2016 300,000 Valued at $0.71 per share Services David Treves 07/27/2016 6,767 Valued at $0.53 per share Services Firstfire Global Opportunities Fund LLC 08/04/2016 31,250 Valued at $0.49 per share Services Guy Shalom 10/11/2016 119,000 $0.40 per share Investment Total Shares Issued 2,677,017 During 2016, the Registrant issued Class A Warrants and Class B Unit Warrants to the following entities for bona fide services to the Registrant. The issuances of these Warrants were in consideration for convertible note payable and was made without registration under the Act in reliance upon the exemptions provided in Section 4(2) of the Act and Reg S. Name of Subscriber Bases for Issuance Date of Issuance Price Per Unit Class A Warrant Issued Class B Warrant Issued Ilan Malca Subscription Agreement 05/24/2016 $ 0.40 100,000 - Alpha Capital Anstalt Subscription Agreement 05/30/2016 $ 0.40 1,000,000 1,000,000 Maz Partners LP Subscription Agreement 03/31/2016 $ 0.40 200,000 - Chi Squared Capital Inc Subscription Agreement 05/30/2016 $ 0.40 100,000 100,000 Firstfire Global Opportunities Fund LLC Subscription Agreement 07/07/2016 $ 0.40 250,000 250,000 Guy Shalom Investment Agreement 10/11/2016 $ 0.40 119,000 - Total Warrants Issued 1,769,000 1,350,000 Recent Option Grants On October 1, 2015, the Company’s board of directors approved a grant of 592,000 options to certain of its employees and consultants. Each option is exercisable to purchase a share of common stock at an exercise price equal to $0.01-$0.4 per share. As of December 31,2016, 561,280 options were fully vested and 30,720 options were canceled. As a result, the Company recognized share-based payment net expenses in 2016 and 2015 in the amount of $141,436 and $398,575 respectively. On February 11, 2016, the Company’s board of directors approved a grant of 70,533 options to certain of its employees. Each option is exercisable to purchase a share of common stock at an exercise price equal to $0.01-$0.4 per share. As of December 31,2016, 47,133 options were fully vested and 31,500 options were canceled. As a result, the Company recognized share-based payment expenses in 2016 in the amount of $21,798. On February 18, 2016, the Company’s board of directors approved a grant of 1,466,700 options to certain of its employees and consultants. Each option is exercisable to purchase a share of common stock at an exercise price equal to $0.01- $0.4 per share. As of December 31,2016, all the options were fully vested. As a result, the Company recognized share-based payment expenses in 2016 in the amount of $1,389,614. On May 5, 2016, the Company’s board of directors approved a grant of 93,750 options to certain of consultants. Each option is exercisable to purchase a share of common stock at an exercise price equal to $0.001 per share. As of December 31, 2016, all the options were fully vested. As a result, the Company recognized share-based payment expenses in 2016 in the amount of $61,455. On October 1, 2016, the Company’s board of directors approved a grant of 2,514,500 options to certain of its executive, director and consultants. Each option is exercisable to purchase a share of common stock at an exercise price equal to $0.001- $0.4 per share. As of December 31, 2016, 1,111,500 options were fully vested and $450,000 thousands were canceled. As a result, the Company recognized share-based payment expenses in 2016 in the amount of $396,222. On November 3, 2016, the Company’s board of directors approved a grant of 339,000 options to certain of its employees. Each option is exercisable to purchase a share of common stock at an exercise price equal to $0.2-$0.4 per share. As of December 31,2016, 139,000 options were fully vested. As a result, the Company recognized share-based payment expenses in 2016 in the amount of $40,747. A summary of the Company’s activity related to options to employees, executives and directors and related information is as follows: For the year ended December 31, 2016 For the year ended December 31, 2015 Amount of options Weighted average exercise price Aggregate intrinsic value Amount of options Weighted average exercise price Aggregate intrinsic value $ $ $ $ Outstanding at beginning of year 561,280 0.0666 - - - Granted 5,440,483 0.1336 592,000 0.06 Exercised (697,086 ) - - - Cancelled (550,000 ) (0.3956 ) (30,720 ) Outstanding at the end of year 4,193,397 0.11 1,006,415 561,280 0.06 527,603 Vested and expected-to-vest at end of period 3,288,062 0.11 789,134 561,280 0.06 527,603 The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between the fair market value of the Company’s common shares on December 31, 2016 and December 31, 2015 respectively and the exercise price, multiplied by the number of in-the-money stock options on those dates) that would have been received by the stock option holders had all stock option holders exercised their stock options on those dates. The stock options outstanding as of December 31, 2016, and December 31, 2015, have been separated into exercise prices, as follows: Exercise price Stock options outstanding as of December 31, Weighted average remaining contractual life – years as of December 31, Stock options exercisable as of December 31, 2016 2015 2016 2015 2016 2015 0.4 1,208,600 78,720 9.25 8.75 1,208,600 78,720 - 0.2 1,870,000 - 9 1,870,000 - (*) 1,114,797 482,560 9.25 8.75 1,114,797 482,560 4,193,397 561,280 9.25 8.75 4,193,397 561,280 (*) Less than 1% Compensation expense recorded by the Company in respect of its stock-based employee compensation awards in accordance with ASC 718-10 for the year ended December 31, 2016 and 2015 was $2,028,805 and $397,547, respectively. The fair value of the stock options is estimated at the date of grant using Black-Scholes options pricing model with the following weighted-average assumptions: Years ended December 31, 2016 2015 Expected volatility 157 % 70.0 % Risk-free interest 0.69 % 1.0 % Dividend yield 0 % 0 % Expected life of up to (years) 6.0 6.0

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2016
Related Party Transactions [Abstract]
Related Party Transactions	Note 3. Related Party Transactions. On July 16, 2015, five holders of Emerald debt with principal amount of $87,910 converted their debt into 274,719 units at a conversion price of $0.32 per unit, each unit comprised of one share of common stock and one Class A warrant exercisable at $0.80 per share with a term of 24 month. The Company recognized Loss on settlement of debt of $678,027 on the statements of operations. On July 14, 2015, the Company issued Emerald’s CEO and founder, Lior Wayn, 5,474,545 shares as per the share purchase agreement valued at $877,380, valued on the date of grant using the closing price of common stock on that date. Following the closing of the reverse merger, the $490,000 loan from Emerald Medical Applications Corp. to Emerald Medical Applications Ltd. was rendered an intercompany loan and as such was written off. The Company’s former CEO, Lior Wayn, was owed $3,252 and $3,480 payable as of December 31, 2016 and December 31, 2015, respectively. On February 18, 2016, the Company issued 1,195,000 shares to three acting directors, for services valued at a total value of $1,194,403, arrived at using the stock price on date of grant of $1.00 per Nasdaq.com. On October 1, 2016, The Company granted its Chairman a total of 180,000 stock options (the “Options”). Of this amount 90,000 Options were fully vested immediately and 90,000 Options over vest periods of 8 quarters. The options are exercisable at prices of $0.20 per Share. The options were valued using the Black-Scholes option pricing model with 113% volatility and 1.14% discount rate for a total value of $64,518. Of this amount, $35,668 was expensed in 2016 with the remaining balance will be expensed in 2017 and 2018, 16,485 and 12,364 respectively.

Employee Payable

Employee Payable	12 Months Ended
	Dec. 31, 2016
Retirement Benefits [Abstract]
Employee Payable	Note 4. Employee Payable. As of December 31, 2016, the Company had a total of $101,341. As of December 31, 2015, the Company had a total of $29,092 of which $3,480 were related party and $25,612 were unrelated party employee payable related to the monthly wages payable to the Company’s employees.

Notes Payable

Notes Payable	12 Months Ended
	Dec. 31, 2016
Notes Payable [Abstract]
Notes Payable	Note 5. Notes Payable Convertible Notes Payable – see note 3 Note Payable - Non-Convertible On July 8, 2014, the Company issued a convertible promissory note to Axel Springer Plug & Play Accelerator GmbH (the “Holder”) in the amount of $29,719. As of December 31, 2015, and 2016, the Company had accrued interest of $2,013 and $0 respectively. As of December 31, 2015, the convertible note is no longer convertible as Axel Springer did not exercise its option to convert upon occurrence of a qualifying event

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 6. Commitments and Contingencies The Company received grants to fund research and development projects from the State of Israel according to guidelines and procedures of the Office of the Chief Scientist of the Ministry of Industry and Trade. According to the agreement, the Company is obligated to pay royalties on the sale of products developed with the participation of the Chief Scientist. The royalty rate is 3.5% of sales and the total royalties will not exceed the amount of the grants received. As of December 31, 2016, total grants received amounted approximately $222 thousands. The obligation to pay royalties is contingent upon the successful outcome of the Company’s research and development projects and the attainment of sales. The Company has no obligation to pay royalties, if sales are not generated, and if the research and development project fails.

Derivative Liabilities from Con

Derivative Liabilities from Convertible Notes - Axel Springer	12 Months Ended
	Dec. 31, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Liabilities from Convertible Notes - Axel Springer	Note 7. Derivative Liabilities from Convertible Notes - Axel Springer The Company values its derivative instruments related to embedded conversion features and warrants from the issuance of convertible debentures in accordance with the Level 3 guidelines. For the twelve-month period ended December 31, 2015, the following table reconciles the beginning and ending balances for financial instruments that are recognized at fair value in these consolidated financial statements. The fair value of embedded conversion features that have floating conversion features and tainted common stock equivalents (warrants and convertible debt) are estimated using a Binomial Lattice model. The key inputs to this valuation model as of December 31, 2015, were: Volatility of 143.9% for the twelve-month period ending December 31, 2015, inherent term of instruments equal to the remaining contractual term, quoted closing stock prices on valuation dates, and various settlement scenarios and probability percentages summing to 100%. Fair Value Measurements at December 31, 2015 Level 3 - Derivative liabilities from: Balance at December 31, 2014 New Issuances Extinguishment Change in Fair Value Balance at December 31, 2015 Convertible Note $ 20,532 $ - $ (20,532 ) - $ - Changes in the unobservable input values would likely cause material changes in the fair value of the Company’s Level 3 financial instruments. The significant unobservable input used in the fair value measurement is the estimation for probability percentages assigned to future expected settlement possibilities. A significant increase (decrease) in this distribution of percentages would result in a higher (lower) fair value measurement. The Company had no liabilities that were measured and recognized at fair value as of December 31, 2016 and December 31, 2015 There were no transfers of financial assets or liabilities between Level 1, Level 2 and Level 3 inputs for the years ended December 31, 2016. The Company had no other assets or liabilities valued at fair value on a recurring or non-recurring basis as of December 31, 2016 or December 31, 2016 and the years then ended.

Other Receivables

Other Receivables	12 Months Ended
	Dec. 31, 2016
Receivables [Abstract]
Other Receivables	Note 8. Other Receivables. As of December 31, 2016, and December 31, 2015, the Company had other receivables of $9,356 and $25,797, respectively, which represent VAT refunds claimed resulting from excess VAT paid over VAT received from the Israeli government.

Accounts Payable and Accrued Li

Accounts Payable and Accrued Liabilities	12 Months Ended
	Dec. 31, 2016
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities	Note 9. Accounts Payable and Accrued Liabilities. As of December 31, 2016, and December 31, 2015 the Company had accounts payable and accrued liabilities of $258,795 and $90,705, respectively, which mainly represent accrued expenses such as accrued vacation and deferred salary.

Litigation Accruals

Litigation Accruals	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Litigation Accruals	Note 10. Litigation Accruals. On November 9, 2015, the Company received a notice of claim from Tomer Maharshak & Co., Israel, the Company’s former attorneys, for legal fees allegedly owed by the Company and its wholly owned Israeli subsidiary, Emerald Medical Applications Ltd. On December 12, 2015 and December 23, 2015, the claim was settled for cash payment and the Company recorded neither a gain nor a loss on the settlement. As of December 31, 2015, the litigation accrual balance is zero and there are currently no ongoing litigations against the Company.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	Note 11. Income Taxes. The Company is subject to income taxes under the Israeli and U.S. tax laws: Corporate tax rates The Company is subject to Israeli corporate tax rate of 26.5% in 2015, 25% in 2016, 24% in 2017 and 23% from 2018. The Company is subject to a blended U.S. tax rate (federal as well as state corporate tax) of 35%. As of December 31, 2016, the Company generated net operating losses in Israel of approximately $2,484,835, which may be carried forward and offset against taxable income in the future for an indefinite period. As of December 31, 2016, the Company generated net operating losses in the U.S. of approximately $14,670,241. Net operating losses in the United States are available through 2035. Utilization of U.S. net operating losses may be subject to substantial annual limitation due to the “change in ownership” provisions of the Internal Revenue Code of 1986 and similar state provisions. The annual limitation may result in the expiration of net operating losses before utilization. The Company is still in its development stage and has not yet generated revenues, therefore, it is more likely than not that sufficient taxable income will not be available for the tax losses to be utilized in the future. Therefore, a valuation allowance was recorded to reduce the deferred tax assets to its recoverable amounts. As of December 31, 2016 2015 (in thousands) Net loss carry-forward $ 17,155,076 $ 471,980 Total deferred tax assets 5,730,945 125,075 Valuation allowance (5,730,945 ) (125,075 ) Net deferred tax assets $ - $ -

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	Note 12. Subsequent Events. On January 26, 2017, Lior Wayn, the Company's former CEO and director, transferred and assigned all of his 5,212,878 shares of common stock and 900,000 of his Class E Warrants to an entity controlled by Alimi Ahmed, who was a newly-appointed director of the Company. Effective on April 2, 2017, Mr. Alimi was appointed as Chairman of the Company’s Board of Directors, replacing Mr. Yair Fudim, who will continue to serve as a member of the Board of Directors. Effective December 31, 2016, the remaining 1.7 million Class E Warrants that had been issued to Mr. Wayn were cancelled. Mrs. Adi Zamir, the Company’s CEO, reported to the Board of Directors on March 26, 2017 that pursuant to the terms of her employment agreement, she would cease serving as CEO effective on June 23, 2017. During the period from March 26, 2017 until June 23, 2017, Mrs. Zamir will continue to serve as CEO unless the Company appoints a new CEO prior to June 23, 2017. If the Company does appoint a new CEO prior to such date, Mrs. Zamir will continue to serve the Company in a non-executive officer capacity, until June 23, 2017. On July 7, 2016, the Company announced that it was awarded first prize of 500,000 Euros or approximately U$526,000, over 3,500 other competing tech companies in the Publicis Groupe 90 initiative at the inaugural edition of Viva Technology Paris. On February 24, 2017, the Registrant accepted a Reg S Subscription Agreement from Publicis 90 in consideration for the issuance to Publicis 90 of 1,315,563 restricted shares of the Registrant’s common stock at a subscription price of $0.40 per share. The issuance was made in reliance upon the exemptions provided in Section 4(2) of the Securities Act of 1933, as amended (the “Act”) and Regulation S promulgated by the SEC under the Act.

The Company and Significant A20

The Company and Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates: The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from the estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents: For financial statement presentation purposes, the Company considers those short-term, highly liquid investments with original maturities of three months or less to be cash or cash equivalents. There were no cash equivalents as of December 31, 2016 and December 31, 2015.
Other Receivables	Other Receivables The Company treats VAT refunds claimed resulting from excess VAT paid over VAT received as other receivables, amount shown as other receivables as of December 31, 2016 was $ 8,234.
Currency Translation and Other Comprehensive Income	Currency Translation and other Comprehensive Income The functional currency of the Emerald Application Corp. is the U.S dollar (“dollar”) since the dollar is the currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future. Transactions and balances denominated in dollars are presented at their original amounts. Transactions and balances denominated in foreign currencies have been re-measured to dollars in accordance with the provisions of ASC 830-10, “Foreign Currency Translation”. All transaction gains and losses from re-measurement of monetary balance sheet items denominated in non-dollar currencies are reflected in the statement of operations as financial income or expenses, as appropriate. Prior to January 1, 2016, Emerald Medial Application Ltd.’s functional currency was the New Israeli Shekel (“NIS”). Translation gains and losses from the application of the U.S. dollar as the reporting currency while the NIS was the functional currency are included as part of cumulative currency translation adjustment, which is reported as a component of shareholders’ equity under accumulated other comprehensive loss. Emerald Medial Application Ltd, re-assessed its functional currency and determined as at January 1, 2016, its functional currency changed from NIS to the U.S. dollar based on management’s analysis of changes in the primary economic environment in which the Company operates. The change in functional currency is accounted for prospectively from January 1, 2016.
Fixed Assets	fixed assets: New property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally 6 years. Expenditures for renewals and betterments are capitalized. Expenditures for minor items, repairs and maintenance are charged to operations as incurred. Gain or loss upon sale or retirement due to obsolescence is reflected in the operating results in the period the event takes place.
Accounting for Obligations and Instruments Potentially to be Settled in the Company's Own Stock	Accounting For Obligations And Instruments Potentially To Be Settled In The Company’s Own Stock: We account for obligations and instruments potentially to be settled in the Company’s stock in accordance with FASB ASC 815, Accounting for Derivative Financial Instruments. This guidance addresses the initial balance sheet classification and measurement of contracts that are indexed to, and potentially settled in, the Company’s own stock. Fair Value of Financial Instruments: FASB ASC 825, “Financial Instruments,” requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value. FASB ASC 825 defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. At December 31, 2015 and 2014, the carrying value of certain financial instruments (cash and cash equivalents, accounts payable and accrued expenses.) approximates fair value due to the short-term nature of the instruments or interest rates, which are comparable with current rates.
Accounting for Convertible Debt Instruments	Accounting For Convertible Debt Instruments We account for convertible debt instruments, which do not meet the definition of a derivative financial instrument per FASB ASC 815, Accounting for Derivative Financial Instruments, in accordance with FASB ASC 470-20, Debt with Conversion and Other Options. This guidance addresses the allocation of proceeds from the issuance of convertible debt into its equity and debt components. Discount on the debt component resulting from allocation of proceeds to the equity component is amortized in the profit and loss statement as finance expense. Allocation of proceeds into equity and debt components of convertible notes issued together with other detachable financial instruments is performed in relation to the proceeds allocated to the convertible notes based on the relative fair value of such convertible notes and the other detachable financial instruments issued.
Share-based Compensation	Share-based compensation The Company applies ASC 718-10, “Share-Based Payment,” which requires the measurement and recognition of compensation expenses for all share-based payment awards made to employees and directors (including employee stock options under the Company’s stock plans) based on estimated fair values. ASC 718-10 requires companies to estimate the fair value of equity-based payment awards on the date of grant. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company’s statement of operations. The Company recognizes compensation expenses for the value of non-employee awards based on the straight-line method over the requisite service period of each award, net of estimated forfeitures. The Company estimates the fair value of stock options granted as equity awards using a Black-Scholes options pricing model. The option-pricing model requires a number of assumptions, of which the most significant are share price, expected volatility and the expected option term (the time from the grant date until the options are exercised or expire). Expected volatility is estimated based on volatility of similar companies in the technology sector. The Company has historically not paid dividends and has no foreseeable plans to issue dividends. The risk-free interest rate is based on the yield from governmental zero-coupon bonds with an equivalent term. The expected option term is calculated for options granted to employees and directors using the “simplified” method. Grants to non-employees are based on the contractual term. Changes in the determination of each of the inputs can affect the fair value of the options granted and the results of operations of the Company.
Fair Value Measurements	Fair Value Measurements: The Company adopted the FASB standard related to fair value measurement at inception. The standard defines fair value, establishes a framework for measuring fair value and expands disclosure of fair value measurements. The standard applies under other accounting pronouncements that require or permit fair value measurements and, accordingly, does not require any new fair value measurements. The standard clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the standard established a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows. Level 1. Observable inputs such as quoted prices in active markets;
Earnings Per Common Share	Earnings per Common Share We compute net income (loss) per share in accordance with ASC 260, Earning per Share. ASC 260 requires presentation of both basic and diluted earnings per share (EPS) on the face of the income statement. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing, Diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive. All per share disclosures retroactively reflect shares outstanding or issuable as though the reverse split had occurred January 1, 2012. The weighted average number of Ordinary Shares outstanding has been retroactively restated for the equivalent number of shares received by the accounting acquirer as a result of the reverse recapitalization as if these shares had been outstanding as of the beginning of the earliest period presented
Research and Development Expenses, Net	Research and development expenses, net: Research and development expenses are charged to the statement of operations as incurred. Grants for funding of approved research and development projects are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred and applied as a deduction from the research and development expenses.
Income Taxes	Income Taxes: We have adopted FASB ASC 740, Accounting for Income Taxes. Pursuant to ASC 740, we are required to compute tax asset benefits for net operating losses carried forward. The potential benefits of net operating losses have not been recognized in these financial statements because the Company cannot be assured it is more likely than not it will utilize the net operating losses carried forward in future years. We must make certain estimates and judgments in determining income tax expense for financial statement purposes. These estimates and judgments occur in the calculation of certain tax assets and liabilities, which arise from differences in the timing of recognition of revenue and expense for tax and financial statement purposes. Deferred tax assets and liabilities are determined based on the differences between financial reporting and the tax basis of assets and liabilities using the tax rates and laws in effect when the differences are expected to reverse. ASC 740 provides for the recognition of deferred tax assets if realization of such assets is more likely than not to occur. Realization of our net deferred tax assets is dependent upon our generating sufficient taxable income in future years in appropriate tax jurisdictions to realize benefit from the reversal of temporary differences and from net operating loss, or NOL, carryforwards. We have determined it more likely than not that these timing differences will not materialize and have provided a valuation allowance against substantially all of our net deferred tax asset. Management will continue to evaluate the realizability of the deferred tax asset and its related valuation allowance. If our assessment of the deferred tax assets or the corresponding valuation allowance were to change, we would record the related adjustment to income during the period in which we make the determination. Our tax rate may also vary based on our results and the mix of income or loss in domestic and foreign tax jurisdictions in which we operate. In addition, the calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax regulations. We recognize liabilities for anticipated tax audit issues in the U.S. and other tax jurisdictions based on our estimate of whether, and to the extent to which, additional taxes will be due. If we ultimately determine that payment of these amounts is unnecessary, we will reverse the liability and recognize a tax benefit during the period in which we determine that the liability is no longer necessary. We will record an additional charge in our provision for taxes in the period in which we determine that the recorded tax liability is less than we expect the ultimate assessment to be. ASC 740 which requires recognition of estimated income taxes payable or refundable on income tax returns for the current year and for the estimated future tax effect attributable to temporary differences and carry-forwards. Measurement of deferred income tax is based on enacted tax laws including tax rates, with the measurement of deferred income tax assets being reduced by available tax benefits not expected to be realized.
Uncertain Tax Positions	Uncertain Tax Positions: When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of FASB ASC 740-10, Accounting for Uncertain Income Tax Positions, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above should be reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In September 2015, the FASB issued ASU No. 2015-16, Business Combinations (Topic 805) (“ASU 2015-16”). Topic 805 requires that an acquirer retrospectively adjust provisional amounts recognized in a business combination, during the measurement period. To simplify the accounting for adjustments made to provisional amounts, the amendments in the Update require that the acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amount is determined. The acquirer is required to also record, in the same period’s financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the provisional amounts, calculated as if the accounting had been completed at the acquisition date. In addition an entity is required to present separately on the face of the income statement or disclose in the notes to the financial statements the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment to the provisional amounts had been recognized as of the acquisition date. ASU 2015-16 is effective for fiscal years beginning December 15, 2015. The adoption of ASU 2015-016 is not expected to have a material effect on the Company’s consolidated financial statements. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date (“ASU 2015-14”). The amendment in this ASU defers the effective date of ASU No. 2014-09 for all entities for one year. Public business entities, certain not-for-profit entities, and certain employee benefit plans should apply the guidance in ASU 2014-09 to annual reporting periods beginning December 15, 2017, including interim reporting periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 31, 2016, including interim reporting periods with that reporting period. In April 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2015-03, Interest-Imputation of Interest (Subtopic 835-30) (“ASU 2015-03”), which changes the presentation of debt issuance costs in financial statements. ASU 2015-03 requires an entity to present such costs in the balance sheet as a direct deduction from the related debt liability rather than as an asset. Amortization of the costs will continue to be reported as interest expense. It is effective for annual reporting periods beginning after December 15, 2016. Early adoption is permitted. The new guidance will be applied retrospectively to each prior period presented. The Company is currently in the process of evaluating the impact of adoption of ASU 2015-03 on its balance sheets. In January 2016, the FASB issued ASU 2016-01 “Recognition and Measurement of Financial Assets and Financial Liabilities”, which provides targeted improvements to the recognition, measurement, presentation and disclosure of financial assets and financial liabilities. Specific accounting areas addressed include, equity investments, financial liabilities reported under the fair value option and valuation allowance assessment resulting from unrealized losses on available-for-sale securities. The standard also changes certain presentation and disclosure requirements for financial instruments. This ASU is effective for the Company in its first quarter of fiscal year 2019. Early adoption, with certain exceptions, is not permitted. The Company does not expect that the adoption of this standard will have a significant impact on the financial position or results of operations. In March 2016, the FASB issued Accounting Standards Update No. 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting (“ASU 2016-09”), which simplifies certain provisions associated with the accounting for stock compensation. Among other things, ASU 2016-09 requires companies to record excess tax benefits and tax deficiencies as income tax benefit or expense in the statement of income and eliminates the requirement to reclassify cash flows related to excess tax benefits from operating activities to financing activities in the statement of cash flows. ASU 2016-09 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016, with early adoption permitted. The Company is currently reviewing and evaluating this guidance and its impact on its consolidated financial statements.

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2016
Equity [Abstract]
Summary of Outstanding Warrants	The following table summarizes information of outstanding warrants as of December 31, 2016: Warrants Warrant Term Exercise Price Exercisable Investors - Class A Warrants (1) 5,918,719 2 years $ 0.80 5,918,719 Investors - Class B Warrants (2) 1,350,000 2 years $ 0.40 1,350,000 Investors - Class C Warrants (3) 5,072,492 (3 ) $ (3 ) 5,536,246 Alimi Ahmed - Class E Warrants (4) 900,000 (4 ) $ 0.0001 900,000 The Class A Warrants were issued in connection with a private placement in reliance upon Regulation S, pursuant to which the Registrant sold a total of 5,918,719 units at a price of $0.40 per unit (the “Units”), each Unit comprised of one Share and one Class A Warrant exercisable at $0.80 per share with a term 24 months. While all of the Class A Warrants are exercisable within 60 days, in fact, none of these warrants will be exercised for the foreseeable future, based upon the exercise price of $0.80 per Share. (2) The Class B Warrants were issued to consultants for bona fide services to the Company and are exercise, on a cashless basis at a price of $0.40 per Share for a period of two years. (3) The Class C Unit Warrants were issued to consultants for bona fide services to the Company, and each Unit is exercisable at a price of $0.40 to purchase one Share of Common Stock and one Class A Warrant which, in turn, is exercisable to purchase one additional Share at a price of $0.80. The Class C Unit Warrants expire ninety (90) days after the effective date of this Registration Statement. (4) A total of 2,700,000 Class E Warrants were issued by the Registrant to Lior Wayn pursuant to the terms of the Share Exchange Agreement and were exercisable in three equal tranches of 900,000 Shares each (the “Tranches”) at an exercise price of $0.0001 per Share, subject to and within 45 days of the Registrant achieving the milestones defined in the Share Exchange Agreement
Schedule of Sale of Unregistered Securities	The sales were made without registration under the Act in reliance upon the exemptions provided in Section 4(2) of the Act and Reg S. Name of Subscriber Bases for Issuance Date of Issuance Price Per Unit Shares Issued Short Trade Ltd (1) Subscription Agreement 06/18/2015 $ 0.40 625,000 Prop Trade Ltd (2) Subscription Agreement 06/18/2015 $ 0.40 375,000 Dr. Ben Zion Weiner Subscription Agreement 06/18/2015 $ 0.40 125,000 RP Holdings (1992) Ltd. (3) Subscription Agreement 06/18/2015 $ 0.40 125,000 Dr. Tank Siak Khim Subscription Agreement 06/18/2015 $ 0.40 250,000 Yoel Yogev Subscription Agreement 06/18/2015 $ 0.40 200,000 Universal Link Ltd (4) Subscription Agreement 06/18/2015 $ 0.40 175,000 Avigdor Hakmon Subscription Agreement 06/18/2015 $ 0.40 62,500 Dr. Shmuel Pasternak Subscription Agreement 06/18/2015 $ 0.40 62,500 Liat Sidi Subscription Agreement 07/21/2015 $ 0.40 25,000 Tzvi Aharonson Subscription Agreement 07/21/2015 $ 0.40 137,500 Estory Giloz Ran Subscription Agreement 07/21/2015 $ 0.40 312,500 Malca Maimon Subscription Agreement 07/21/2015 $ 0.40 87,500 Ohad Cohen Subscription Agreement 07/21/2015 $ 0.40 150,000 Nissim Simhon Subscription Agreement 07/21/2015 $ 0.40 50,000 NE Solution Ltd (5) Subscription Agreement 07/21/2015 $ 0.40 162,500 Total $ 1,169,961 2,925,000 (1) Short Trade Ltd is controlled by Mr. Shlomo Noyman, a resident of Israel. (2) Prop Trade Ltd is controlled by Mr. Andrew Philip Dings, a resident of Singapore. (3) RP Holdings (1992) Ltd. is controlled by Mr. Rubin Zimerman, a resident of Israel. (4) Universal Link Ltd is controlled by Mr. Ahmad Alimi, a resident of Israel. (5) NE Solution Ltd is controlled by Mr. Lee Yang Tong, a resident of Singapore.
Schedule of Debt Owed Listed Persons	Each of the lenders was a resident of Israel and the issuance was without registration under the Act in reliance upon the exemptions provided in Section 4(2) of the Act and Reg S. Name of Note Holder Bases of Issuance Debt Converted Shares Issued David Masasa Conversion of Debt $ 8,788 27,463 Liron Carmel Conversion of Debt $ 19,521 61,003 Yoseph Cohen Conversion of Debt $ 15,632 48,850 Tzvi Aharonson Conversion of Debt $ 43,969 137,403 Total $ 87,910 274,719
Schedule of Issuance of Warrant Consideration for Services	Basis of Issuance Class B Warrant Issued Class C Unit Warrants Issued Total Warrants Issued Yaad Consulting Ltd. (1) Services 625,000 $ 634,063 1,259,063 LA Pure Capital Ltd. (2) Services 375,000 $ 380,467 755,467 Amir Uziel Economic Consultant Ltd. (3) Services 625,000 $ 634,061 1,259,061 Capitalink Ltd. (4) Services 625,000 $ 634,061 1,259,061 (1) The control person of Yaad Consulting Ltd is Itschak Shrem, a resident of Israel.
Schedule of Registrant Issued and Sold Unregistered Shares	During November 2015, the Registrant issued and sold unregistered Shares as set forth on the table below: Name of Issuee Date of Issuance Number of Shares Consideration Bases for Issuance Shirat Hahayim 11/17/2015 250,000 $0.40 per share Subscription Agreement (1) Lyons Capital LLC. (2) 11/05/2015 250,000 Valued at $1.00 per share Services David Treves 11/16/2015 12,334 Valued at $1.00 per share Services Pnina Rosenblum 11/09/2015 5,750 Valued at $1.00 per share Services Total Shares Issued 518,084 (1) The issuance was pursuant to a Unit Subscription Agreement each consisting of 1 Share and 1 Class A Warrant exercisable for a period of 24 months to purchase 1 additional Share at $0.80.
Schedule of Registrant Issued and Sold Common Shares	During 2016, the Registrant issued and sold common Shares as set forth on the table below: Name of Issuee Date of Issuance Number of Shares Consideration Bases for Issuance Yair Fudim 02/18/2016 482,000 Valued at $0.9995 per share Services Estery Giloz Ran 02/18/2016 482,000 Valued at $0.9995 per share Services Baruch Kfir 02/18/2016 231,000 Valued at $0.9995 per share Services Legend Securities Inc 03/17/2016 50,000 Valued at $0.65per share Services JFS Investments PR LLC 01/26/2016 125,000 Valued at $1.75 per share Services Garden state securities Inc 05/04/2016 150,000 Valued at $0.70 per share Services JFS Investments PR LLC 05/10/2016 41,667 Valued at $0.71 per share Services Kodiak Capital Group LLc 05/18/2016 150,000 Valued at $0.68 per share Services Alpha Capital Anstalt 06/26/2016 125,000 Valued at $0.70 per share Services Legend Securities Inc 06/28/2016 50,000 Valued at $0.70 per share Services JFS Investments PR LLC 06/30/2016 333,333 Valued at $0.68 per share Services VAR Growth Corporation 07/01/2016 300,000 Valued at $0.71 per share Services David Treves 07/27/2016 6,767 Valued at $0.53 per share Services Firstfire Global Opportunities Fund LLC 08/04/2016 31,250 Valued at $0.49 per share Services Guy Shalom 10/11/2016 119,000 $0.40 per share Investment Total Shares Issued 2,677,017
Schedule of Warrant Issuance of Consideration for Convertible Note Payable Made Without Registration	Name of Subscriber Bases for Issuance Date of Issuance Price Per Unit Class A Warrant Issued Class B Warrant Issued Ilan Malca Subscription Agreement 05/24/2016 $ 0.40 100,000 - Alpha Capital Anstalt Subscription Agreement 05/30/2016 $ 0.40 1,000,000 1,000,000 Maz Partners LP Subscription Agreement 03/31/2016 $ 0.40 200,000 - Chi Squared Capital Inc Subscription Agreement 05/30/2016 $ 0.40 100,000 100,000 Firstfire Global Opportunities Fund LLC Subscription Agreement 07/07/2016 $ 0.40 250,000 250,000 Guy Shalom Investment Agreement 10/11/2016 $ 0.40 119,000 - Total Warrants Issued 1,769,000 1,350,000
Summary of Stock Option Activity	A summary of the Company’s activity related to options to employees, executives and directors and related information is as follows: For the year ended December 31, 2016 For the year ended December 31, 2015 Amount of options Weighted average exercise price Aggregate intrinsic value Amount of options Weighted average exercise price Aggregate intrinsic value $ $ $ $ Outstanding at beginning of year 561,280 0.0666 - - - Granted 5,440,483 0.1336 592,000 0.06 Exercised (697,086 ) - - - Cancelled (550,000 ) (0.3956 ) (30,720 ) Outstanding at the end of year 4,193,397 0.11 1,006,415 561,280 0.06 527,603 Vested and expected-to-vest at end of period 3,288,062 0.11 789,134 561,280 0.06 527,603
Schedule of Stock Options Outstanding Exercise Price Range	The stock options outstanding as of December 31, 2016, and December 31, 2015, have been separated into exercise prices, as follows: Exercise price Stock options outstanding as of December 31, Weighted average remaining contractual life – years as of December 31, Stock options exercisable as of December 31, 2016 2015 2016 2015 2016 2015 0.4 1,208,600 78,720 9.25 8.75 1,208,600 78,720 - 0.2 1,870,000 - 9 1,870,000 - (*) 1,114,797 482,560 9.25 8.75 1,114,797 482,560 4,193,397 561,280 9.25 8.75 4,193,397 561,280 (*) Less than 1%
Schedule of Fair value Assumptions	The fair value of the stock options is estimated at the date of grant using Black-Scholes options pricing model with the following weighted-average assumptions: Years ended December 31, 2016 2015 Expected volatility 157 % 70.0 % Risk-free interest 0.69 % 1.0 % Dividend yield 0 % 0 % Expected life of up to (years) 6.0 6.0

Derivative Liabilities from C22

Derivative Liabilities from Convertible Notes - Axel Springer (Tables)	12 Months Ended
	Dec. 31, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Fair Value Measurement Reccurring Basis	Fair Value Measurements at December 31, 2015 Level 3 - Derivative liabilities from: Balance at December 31, 2014 New Issuances Extinguishment Change in Fair Value Balance at December 31, 2015 Convertible Note $ 20,532 $ - $ (20,532 ) - $ -

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets	As of December 31, 2016 2015 (in thousands) Net loss carry-forward $ 17,155,076 $ 471,980 Total deferred tax assets 5,730,945 125,075 Valuation allowance (5,730,945 ) (125,075 ) Net deferred tax assets $ - $ -

The Company and Significant A24

The Company and Significant Accounting Policies (Details Narrative) - USD ($)	Jul. 14, 2015	Mar. 16, 2015	Dec. 31, 2016	Dec. 31, 2015	Nov. 17, 2015
Warrant exercise price per share					$ 0.80
Cash equivalents
Other receivables			$ 9,356	$ 25,797
Property and equipment estimated useful lives			6 years
Other Receivables VAT [Member]
Other receivables			$ 8,234
Share Exchange Agreement [Member]
Issue of ordinary shares		5,474,545
Percentage of common stock outstanding		45.00%
Share Exchange Agreement [Member] | Shareholders [Member]
Warrant exercise price per share	$ 2.7
Number of common stock shares issued	5,474,545
Percentage of ordinary shares in exchange	100.00%
Share Exchange Agreement [Member] | Chief Executive Officer and Founder [Member]
Number of warrant exercisable shares of common stock		2,700,000
Warrant exercise price per share		$ 0.0001
Additional percentage of common stock outstanding after exercise		21.00%
Number of common stock shares issued	5,474,545
Share Exchange Agreement [Member] | Chief Executive Officer and Founder [Member] | Tranche 1 [Member]
Number of warrant exercisable shares of common stock		900,000
Share Exchange Agreement [Member] | Chief Executive Officer and Founder [Member] | Tranche 2 [Member]
Number of warrant exercisable shares of common stock		900,000
Share Exchange Agreement [Member] | Chief Executive Officer and Founder [Member] | Tranche 3 [Member]
Number of warrant exercisable shares of common stock		900,000

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative) - USD ($)	Nov. 10, 2016	Nov. 03, 2016	Oct. 03, 2016	Aug. 04, 2016	Jul. 07, 2016	Jul. 02, 2016	Jun. 30, 2016	Jun. 28, 2016	Jun. 06, 2016	May 18, 2016	May 10, 2016	May 05, 2016	Apr. 11, 2016	Mar. 24, 2016	Feb. 18, 2016	Feb. 11, 2016	Jan. 26, 2016	Nov. 17, 2015	Nov. 16, 2015	Oct. 03, 2015	Jul. 31, 2015	Jul. 21, 2015	Jul. 16, 2015	Jul. 14, 2015	Jan. 08, 2015	Mar. 17, 2016	Mar. 15, 2015	Sep. 30, 2015	Jun. 29, 2015	Dec. 31, 2016	Dec. 31, 2015	Nov. 30, 2015
Common stock, shares authorized																														490,000,000	490,000,000
Sale of stock, number of shares issued in transaction																		250,000				140,000					2,052,000	862,500	1,012,500
Sale of stock, consideration received on transaction																		$ 100,000				$ 15,000					$ 780,000	$ 345,000	$ 405,000
Shares issued, price per share																		$ 0.40				$ 0.107					$ 0.40	$ 0.40	$ 0.40
Warrant exercise price per share																		$ 0.80
Warrant term																		24 months
Stock issued during period, value, issued for services																														$ 2,263,302	$ 885,984
Debt conversion of units, value																															769,713
Loss on settlement of debt																															$ (678,027)
Fair value assumptions, expected volatility rate																		149.00%													143.90%
Discount rate																		0.50%
Fair value of stock with embedded warrants																		$ 41,304
Debt discount																														$ 305,417	$ 0
Share issued																														2,925,000		518,084
Options, grants																														5,440,483	592,000
Number of options canceled																														(550,000)	(30,720)
Sale of Unregistered Securities [Member]
Shares issued, price per share																						$ 0.40
Share issued																						2,925,000
Sale of Unregistered Securities [Member] | Common Stock [Member]
Shares issued, price per share																						$ 0.80
Share Purchase Agreement [Member]
Stock issued during period, shares, new issues																								5,474,545
Stock issued during period, value, new issues																								$ 877,380
Class A warrant [Member]
Warrant exercise price per share																						$ 0.80	$ 0.80				$ 0.80	$ 0.80	$ 0.80	$ 0.80
Warrant term																						24 months	24 months				24 months	24 months	24 months	24 months
Fair value of stock with embedded warrants																		$ 58,696
Conversion price of restricted share and warrant																														$ 0.32
Closing Reverse Merger [Member]
Sale of stock, number of shares issued in transaction																												65,000
Sale of stock, consideration received on transaction																												$ 280,000
Class B warrant [Member]
Shares issued, price per share																	$ 0.40						$ 0.40
Warrant exercise price per share																														$ 0.40
Warrant term																	2 years													2 years
Warrants issued																	2,500,000						2,500,000
Fair value adjustment of warrants																							$ 2,199,507
Fair value assumptions, expected volatility rate																							182.00%
Discount rate																							0.67%
Class C warrant [Member]
Shares issued, price per share																							$ 0.40
Warrant exercise price per share																							$ 0.80
Warrant term																							90 days							90 days
Warrants issued																							2,536,247
Fair value adjustment of warrants																							$ 3,143,581
Fair value assumptions, expected volatility rate																							182.00%
Discount rate																							0.67%
Warrant [Member]
Warrants issued																	1,928,572
Class E warrant [Member]
Warrant exercise price per share																														$ 0.0001
Board of Directors [Member]
Reverse stock split																									ratio of 1:4
One Service Provider [Member]
Shares issued, price per share				$ 0.49		$ 0.71	$ 0.68			$ 0.68	$ 0.71	$ 0.7									$ 1					$ 1.75
Stock issued during period, shares, issued for services				31,250		300,000	333,333			150,000	41,667	150,000									517,900					125,000
Stock issued during period, value, issued for services				$ 15,313		$ 213,000	$ 226,666			$ 102,000	$ 29,584	$ 105,000									$ 617,900					$ 251,250
Two Service Provider [Member]
Shares issued, price per share																					$ 1					$ 0.65
Stock issued during period, shares, issued for services																					100,000					50,000
Stock issued during period, value, issued for services																					$ 617,900					$ 251,250
Five Emerald Debt Holders [Member]
Shares issued, price per share																							$ 0.32
Debt conversion of units, value																							$ 87,910
Debt conversion of units, shares																							274,719
Loss on settlement of debt																							$ 678,027
Three Service Provider [Member]
Shares issued, price per share								$ 0.7											$ 1
Stock issued during period, shares, issued for services								175,000											268,084
Stock issued during period, value, issued for services								$ 122,500											$ 268,084
Three Acting Directors [Member]
Shares issued, price per share															$ 1
Stock issued during period, shares, issued for services															1,195,000
Stock issued during period, value, issued for services															$ 1,194,403
Maz Partner [Member]
Convertible, beneficial conversion feature													$ 80,000
Debt discount													$ 80,000
Ilan Malka [Member]
Convertible, beneficial conversion feature							40,000
Debt discount							$ 40,000
One Service Provider A [Member]
Shares issued, price per share						$ 0.53
Stock issued during period, shares, issued for services						6,767
Stock issued during period, value, issued for services						$ 3,587
Guy Shalom [Member]
Warrant exercise price per share	$ 0.8
Stock issued during period, shares, new issues	119,000
Stock issued during period, value, new issues	$ 47,600
Warrants exercisable	$ 119,000
Class of warrant or right, number of securities called by warrants or rights	119,000
Mr. Wayn [Member]
Sale of stock, number of shares issued in transaction																														5,212,878
Warrants issued, remaining																														1,800,000
Mr. Alimi Ahmed [Member] | Class E warrant [Member]
Number of warrants vested																														900,000
Shira Brand Shiffer [Member] | Restricted Stock [Member]
Shares issued, price per share																						$ 0.107
Restricted shares																						140,000
Employees and Consultants [Member] | Recent Option Grants 1 [Member]
Options, grants																				592,000
Exercise price range, lower range limit																				$ 0.01
Exercise price range, upper range limit																				$ 0.4
Share-based payment net of expenses																														$ 141,436	$ 398,575
Employees and Consultants [Member] | Recent Option Grants 3 [Member]
Options, grants															1,466,700
Exercise price range, lower range limit															$ 0.01
Exercise price range, upper range limit															$ 0.4
Share-based payment net of expenses																														1,389,614
Employees [Member] | Recent Option Grants 2 [Member]
Options, grants																70,533
Exercise price range, lower range limit																$ 0.01
Exercise price range, upper range limit																$ 0.4
Share-based payment net of expenses																														$ 21,798
Employees [Member] | Recent Option Grants 6 [Member]
Options, grants		339,000
Exercise price range, lower range limit		$ 0.2
Exercise price range, upper range limit		$ 0.4
Number of options fully vested																														139,000
Share-based payment net of expenses																														$ 40,747
Consultants [Member] | Recent Option Grants 4 [Member]
Shares issued, price per share												$ 0.001
Options, grants												93,750
Share-based payment net of expenses																														$ 61,455
Executive, Director and Consultants [Member] | Recent Option Grants 5 [Member]
Options, grants			2,514,500
Exercise price range, lower range limit			$ 0.001
Exercise price range, upper range limit			$ 0.4
Number of options fully vested																														1,111,500
Number of options canceled																														450,000
Share-based payment net of expenses																														$ 396,222
Employee [Member]
Share-based payment net of expenses																														$ 2,028,805	$ 397,547
Delaware General Corporation Law [Member] | Minimum [Member]
Common stock, shares authorized																									100,000,000
Delaware General Corporation Law [Member] | Maximum [Member]
Common stock, shares authorized																									490,000,000
GoldMed Ltd [Member]
Convertible note payable and warrants issued														$ 75,000
Convertible, beneficial conversion feature														75,000
Debt discount														$ 75,000
Alpha Capital [Member]
Convertible, beneficial conversion feature									$ 440,000
Debt discount									$ 440,000
Firstfire Global Opportunities Fund LTC [Member]
Convertible, beneficial conversion feature					$ 100,000
Debt discount					$ 100,000
Meyda Consulting Ltd [Member] | Restricted Stock [Member]
Restricted shares																							517,900

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Outstanding Warrants (Details) - $ / shares		Jan. 26, 2016	Nov. 17, 2015	Jul. 21, 2015	Jul. 16, 2015	Mar. 15, 2015	Sep. 30, 2015	Jun. 29, 2015	Dec. 31, 2016
Warrant Term			24 months
Warrant Exercise Price			$ 0.80
Class A warrant [Member]
Warrant Term				24 months	24 months	24 months	24 months	24 months	24 months
Warrant Exercise Price				$ 0.80	$ 0.80	$ 0.80	$ 0.80	$ 0.80	$ 0.80
Class B warrant [Member]
Warrant Term		2 years							2 years
Warrant Exercise Price									$ 0.40
Class C warrant [Member]
Warrant Term					90 days				90 days
Warrant Exercise Price					$ 0.80
Class E warrant [Member]
Warrant Exercise Price									$ 0.0001
Class E warrant [Member] | Alimi Ahmed [Member]
Warrants	[1]								900,000
Warrant Term	[1]								0 years
Warrant Exercise Price	[1]								$ 0.0001
Warrant Exercisable	[1]								900,000
Investors [Member] | Class A warrant [Member]
Warrants	[2]								5,918,719
Warrant Term	[2]								2 years
Warrant Exercise Price	[2]								$ 0.80
Warrant Exercisable	[2]								5,918,719
Investors [Member] | Class B warrant [Member]
Warrants	[3]								1,350,000
Warrant Term	[3]								2 years
Warrant Exercise Price	[3]								$ 0.40
Warrant Exercisable	[3]								1,350,000
Investors [Member] | Class C warrant [Member]
Warrants	[4]								5,072,492
Warrant Term	[4]								0 years
Warrant Exercise Price	[4]
Warrant Exercisable	[4]								5,536,246
[1]	A total of 2,700,000 Class E Warrants were issued by the Registrant to Lior Wayn pursuant to the terms of the Share Exchange Agreement and were exercisable in three equal tranches of 900,000 Shares each (the "Tranches") at an exercise price of $0.0001 per Share, subject to and within 45 days of the Registrant achieving the milestones defined in the Share Exchange Agreement
[2]	The Class A Warrants were issued in connection with a private placement in reliance upon Regulation S, pursuant to which the Registrant sold a total of 5,918,719 units at a price of $0.40 per unit (the "Units"), each Unit comprised of one Share and one Class A Warrant exercisable at $0.80 per share with a term 24 months. While all of the Class A Warrants are exercisable within 60 days, in fact, none of these warrants will be exercised for the foreseeable future, based upon the exercise price of $0.80 per Share.
[3]	The Class B Warrants were issued to consultants for bona fide services to the Company and are exercise, on a cashless basis at a price of $0.40 per Share for a period of two years.
[4]	The Class C Unit Warrants were issued to consultants for bona fide services to the Company, and each Unit is exercisable at a price of $0.40 to purchase one Share of Common Stock and one Class A Warrant which, in turn, is exercisable to purchase one additional Share at a price of $0.80. The Class C Unit Warrants expire ninety (90) days after the effective date of this Registration Statement.

Stockholders' Equity - Summar27

Stockholders' Equity - Summary of Outstanding Warrants (Details) (Parenthetical) - $ / shares	Jan. 26, 2016	Nov. 17, 2015	Jul. 21, 2015	Jul. 16, 2015	Mar. 15, 2015	Sep. 30, 2015	Jun. 29, 2015	Dec. 31, 2016
Warrant term		24 months
Warrant exercise price		$ 0.80
Class A warrant [Member]
Issuance of warrants								5,918,719
Warrant price per unit								$ 0.40
Warrant exercisable price								$ 0.80
Warrant term			24 months	24 months	24 months	24 months	24 months	24 months
Warrant exercise price			$ 0.80	$ 0.80	$ 0.80	$ 0.80	$ 0.80	$ 0.80
Class B warrant [Member]
Warrant term	2 years							2 years
Warrant exercise price								$ 0.40
Class C warrant [Member]
Warrant exercisable price								$ 0.80
Warrant term				90 days				90 days
Warrant exercise price				$ 0.80
Class C warrant [Member] | Common Stock [Member]
Warrant exercisable price								$ 0.40
Class E warrant [Member]
Issuance of warrants								2,700,000
Warrant exercise price								$ 0.0001
Class E warrant [Member] | Tranche 1 [Member]
Issuance of warrants								900,000
Class E warrant [Member] | Tranche 2 [Member]
Issuance of warrants								900,000
Class E warrant [Member] | Tranche 3 [Member]
Issuance of warrants								900,000

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Sale of Unregistered Securities (Details) - USD ($)		12 Months Ended
		Dec. 31, 2016	Nov. 30, 2015	Nov. 17, 2015	Sep. 30, 2015	Jul. 21, 2015	Jun. 29, 2015	Mar. 15, 2015
Price Per Unit				$ 0.40	$ 0.40	$ 0.107	$ 0.40	$ 0.40
Shares Issued		2,925,000	518,084
Sale of unregistered securities value of total units		$ 1,169,961
Subscription Agreement [Member] | Dr Ben Zion Weiner [Member]
Date of Issuance		Jun. 18, 2015
Price Per Unit		$ 0.40
Shares Issued		125,000
Subscription Agreement [Member] | Dr. Tank Siak Khim [Member]
Date of Issuance		Jun. 18, 2015
Price Per Unit		$ 0.40
Shares Issued		250,000
Subscription Agreement [Member] | Yoel Yogev [Member]
Date of Issuance		Jun. 18, 2015
Price Per Unit		$ 0.40
Shares Issued		200,000
Subscription Agreement [Member] | Avigdor Hakmon [Member]
Date of Issuance		Jun. 18, 2015
Price Per Unit		$ 0.40
Shares Issued		62,500
Subscription Agreement [Member] | Dr. Shmuel Pasternak [Member]
Date of Issuance		Jun. 18, 2015
Price Per Unit		$ 0.40
Shares Issued		62,500
Subscription Agreement [Member] | Liat Sidi [Member]
Date of Issuance		Jul. 21, 2015
Price Per Unit		$ 0.40
Shares Issued		25,000
Subscription Agreement [Member] | Tzvi Aharonson [Member]
Date of Issuance		Jul. 21, 2015
Price Per Unit		$ 0.40
Shares Issued		137,500
Subscription Agreement [Member] | Estory Giloz Ran [Member]
Date of Issuance		Jul. 21, 2015
Price Per Unit		$ 0.40
Shares Issued		312,500
Subscription Agreement [Member] | Malca Maimon [Member]
Date of Issuance		Jul. 21, 2015
Price Per Unit		$ 0.40
Shares Issued		87,500
Subscription Agreement [Member] | Ohad Cohent [Member]
Date of Issuance		Jul. 21, 2015
Price Per Unit		$ 0.40
Shares Issued		150,000
Subscription Agreement [Member] | Nissim Simhon [Member]
Date of Issuance		Jul. 21, 2015
Price Per Unit		$ 0.40
Shares Issued		50,000
Short Trade Ltd [Member] | Subscription Agreement [Member]
Date of Issuance	[1]	Jun. 18, 2015
Price Per Unit	[1]	$ 0.40
Shares Issued	[1]	625,000
Prop Trade Ltd [Member] | Subscription Agreement [Member]
Date of Issuance	[2]	Jun. 18, 2015
Price Per Unit	[2]	$ 0.40
Shares Issued	[2]	375,000
RP Holdings Ltd [Member] | Subscription Agreement [Member]
Date of Issuance	[3]	Jun. 18, 2015
Price Per Unit	[3]	$ 0.40
Shares Issued	[3]	125,000
Universal Link Ltd [Member] | Subscription Agreement [Member]
Date of Issuance	[4]	Jun. 18, 2015
Price Per Unit	[4]	$ 0.40
Shares Issued	[4]	175,000
NE Solution Ltd [Member] | Subscription Agreement [Member]
Date of Issuance	[5]	Jul. 21, 2015
Price Per Unit	[5]	$ 0.40
Shares Issued	[5]	162,500
[1]	Short Trade Ltd is controlled by Mr. Shlomo Noyman, a resident of Israel.
[2]	Prop Trade Ltd is controlled by Mr. Andrew Philip Dings, a resident of Singapore.
[3]	RP Holdings (1992) Ltd. is controlled by Mr. Rubin Zimerman, a resident of Israel.
[4]	Universal Link Ltd is controlled by Mr. Ahmad Alimi, a resident of Israel.
[5]	NE Solution Ltd is controlled by Mr. Lee Yang Tong, a resident of Singapore.

Stockholders' Equity - Schedu29

Stockholders' Equity - Schedule of Debt Owed Listed Persons (Details)	1 Months Ended
	Jul. 31, 2015USD ($)shares
Debt Converted | $	$ 87,910
Shares Issued | shares	274,719
David Masasa [Member] | Conversion of Debt [Member]
Debt Converted | $	$ 8,788
Shares Issued | shares	27,463
Liron Carmel [Member] | Conversion of Debt [Member]
Debt Converted | $	$ 19,521
Shares Issued | shares	61,003
Yoseph Cohen [Member] | Conversion of Debt [Member]
Debt Converted | $	$ 15,632
Shares Issued | shares	48,850
Tzvi Aharonson [Member] | Conversion of Debt [Member]
Debt Converted | $	$ 43,969
Shares Issued | shares	137,403

Stockholders' Equity - Schedu30

Stockholders' Equity - Schedule of Issuance of Warrant Consideration for Services (Details) - shares		Jan. 26, 2016	Jul. 16, 2015
Class B warrant [Member]
Warrants Issued		2,500,000	2,500,000
Yaad Consulting Ltd [Member] | Services [Member]
Warrants Issued	[1]		1,259,036
Yaad Consulting Ltd [Member] | Services [Member] | Class B warrant [Member]
Warrants Issued	[1]		625,000
Yaad Consulting Ltd [Member] | Services [Member] | Class C Unit warrants [Member]
Warrants Issued	[1]		634,063
LA Pure Capital Ltd [Member] | Services [Member]
Warrants Issued	[2]		755,467
LA Pure Capital Ltd [Member] | Services [Member] | Class B warrant [Member]
Warrants Issued	[2]		375,000
LA Pure Capital Ltd [Member] | Services [Member] | Class C Unit warrants [Member]
Warrants Issued	[2]		380,467
Amir Uziel Economic Consultant Ltd [Member] | Services [Member]
Warrants Issued	[3]		1,259,061
Amir Uziel Economic Consultant Ltd [Member] | Services [Member] | Class B warrant [Member]
Warrants Issued	[3]		625,000
Amir Uziel Economic Consultant Ltd [Member] | Services [Member] | Class C Unit warrants [Member]
Warrants Issued	[3]		634,061
Capitalink Ltd [Member] | Services [Member]
Warrants Issued	[4]		1,259,061
Capitalink Ltd [Member] | Services [Member] | Class B warrant [Member]
Warrants Issued	[4]		625,000
Capitalink Ltd [Member] | Services [Member] | Class C Unit warrants [Member]
Warrants Issued	[4]		634,061
[1]	The control person of Yaad Consulting Ltd is Itschak Shrem, a resident of Israel.
[2]	The control person of LA Pure Capital Ltd is Kfir Silberman, a resident of Israel.
[3]	The control person of Amir Uziel Economic Consultant Ltd. is Amir Uziel, a resident of Israel.
[4]	The control person of Captalink Ltd is Lavi Krasney, a resident of Israel.

Stockholders' Equity - Schedu31

Stockholders' Equity - Schedule of Registrant Issued and Sold Uregistered Shares (Details) - $ / shares		1 Months Ended	12 Months Ended
		Nov. 30, 2015	Dec. 31, 2016
Number of Shares		518,084	2,925,000
Lyons Capital LLC [Member] | Services [Member]
Date of Issuance	[1]	Nov. 5, 2015
Number of Shares	[1]	250,000
Consideration	[1]	$ 1
Shirat Hahayim [Member] | Subscription Agreement [Member]
Date of Issuance	[2]	Nov. 17, 2015
Number of Shares	[2]	250,000
Consideration	[2]	$ 0.40
David Treves [Member] | Services [Member]
Date of Issuance		Nov. 16, 2015	Jul. 27, 2016
Number of Shares		12,334	6,767
Consideration		$ 1	$ 0.53
Pnina Rosenblum [Member] | Services [Member]
Date of Issuance		Nov. 9, 2015
Number of Shares		5,750
Consideration		$ 1
[1]	Lyons Capital LLC is organized under the laws of Florida and its control person, Jason Lyons, is a resident of Florida.
[2]	The issuance was pursuant to a Unit Subscription Agreement each consisting of 1 Share and 1 Class A Warrant exercisable for a period of 24 months to purchase 1 additional Share at $0.80.

Stockholders' Equity - Schedu32

Stockholders' Equity - Schedule of Registrant Issued and Sold Uregistered Shares (Details) (Parenthetical) - $ / shares	Dec. 31, 2016	Nov. 30, 2015	Nov. 17, 2015	Sep. 30, 2015	Jul. 21, 2015	Jul. 16, 2015	Jun. 29, 2015	Mar. 15, 2015
Warrant Exercise Price			$ 0.80
Class A warrant [Member]
Warrant Exercise Price	$ 0.80			$ 0.80	$ 0.80	$ 0.80	$ 0.80	$ 0.80
Unit Subscription Agreement [Member] | Class A warrant [Member]
Warrant Exercise Price		$ 0.80

Stockholders' Equity - Schedu33

Stockholders' Equity - Schedule of Registrant Issued and Sold Common Shares (Details) - $ / shares	1 Months Ended	12 Months Ended
	Nov. 30, 2015	Dec. 31, 2016
Number of Shares	518,084	2,925,000
Common Shares [Member]
Number of Shares		2,677,017
Services [Member] | Legend Securities Inc [Member]
Date of Issuance		Mar. 17, 2016
Number of Shares		50,000
Consideration		$ 0.65
Services [Member] | JFS Investments PR LLC [Member]
Date of Issuance		Jan. 26, 2016
Number of Shares		125,000
Consideration		$ 1.75
Services [Member] | Garden State Securities Inc [Member]
Date of Issuance		May 4, 2016
Number of Shares		150,000
Consideration		$ 0.70
Services [Member] | JFS Investments PR LLC One [Member]
Date of Issuance		May 10, 2016
Number of Shares		41,667
Consideration		$ 0.71
Services [Member] | Kodiak Capital Group LLC [Member]
Date of Issuance		May 18, 2016
Number of Shares		150,000
Consideration		$ 0.68
Services [Member] | Alpha Capital Anstalt [Member]
Date of Issuance		Jun. 26, 2016
Number of Shares		125,000
Consideration		$ 0.70
Services [Member] | Legend Securities Inc One [Member]
Date of Issuance		Jun. 28, 2016
Number of Shares		50,000
Consideration		$ 0.70
Services [Member] | JFS Investments PR LLC Two [Member]
Date of Issuance		Jun. 30, 2016
Number of Shares		333,333
Consideration		$ 0.68
Services [Member] | VAR Growth Corporation [Member]
Date of Issuance		Jul. 1, 2016
Number of Shares		300,000
Consideration		$ 0.71
Services [Member] | Firstfire Global Opportunities Fund LLC [Member]
Date of Issuance		Aug. 4, 2016
Number of Shares		31,250
Consideration		$ 0.49
Yair Fudim [Member] | Services [Member]
Date of Issuance		Feb. 18, 2016
Number of Shares		482,000
Consideration		$ 0.9995
Estery Giloz Ran [Member] | Services [Member]
Date of Issuance		Feb. 18, 2016
Number of Shares		482,000
Consideration		$ 0.9995
Baruch Kfir [Member] | Services [Member]
Date of Issuance		Feb. 18, 2016
Number of Shares		231,000
Consideration		$ 0.9995
David Treves [Member] | Services [Member]
Date of Issuance	Nov. 16, 2015	Jul. 27, 2016
Number of Shares	12,334	6,767
Consideration	$ 1	$ 0.53
Guy Shalom [Member] | Investment [Member]
Date of Issuance		Oct. 11, 2016
Number of Shares		119,000
Consideration		$ 0.40

Stockholders' Equity - Schedu34

Stockholders' Equity - Schedule of Warrant Issuance of Consideration for Convertible Note Payable Made Without Registration (Details) - $ / shares	12 Months Ended
	Dec. 31, 2016	Jan. 26, 2016	Nov. 17, 2015	Sep. 30, 2015	Jul. 21, 2015	Jul. 16, 2015	Jun. 29, 2015	Mar. 15, 2015
Warrant Exercise Price			$ 0.80
Class A warrant [Member]
Warrant Exercise Price	$ 0.80			$ 0.80	$ 0.80	$ 0.80	$ 0.80	$ 0.80
Class B warrant [Member]
Warrant Exercise Price	$ 0.40
Warrants Issued		2,500,000				2,500,000
Subscription Agreement [Member] | Class A warrant [Member]
Warrants Issued	1,769,000
Subscription Agreement [Member] | Class B warrant [Member]
Warrants Issued	1,350,000
Ilan Malca [Member] | Subscription Agreement [Member] | Class A warrant [Member]
Date of Issuance	May 24, 2016
Warrant Exercise Price	$ 0.40
Warrants Issued	100,000
Ilan Malca [Member] | Subscription Agreement [Member] | Class B warrant [Member]
Date of Issuance	May 24, 2016
Warrant Exercise Price	$ 0.40
Warrants Issued
Alpha Capital Anstalt [Member] | Subscription Agreement [Member] | Class A warrant [Member]
Date of Issuance	May 30, 2016
Warrant Exercise Price	$ 0.40
Warrants Issued	1,000,000
Alpha Capital Anstalt [Member] | Subscription Agreement [Member] | Class B warrant [Member]
Date of Issuance	May 30, 2016
Warrant Exercise Price	$ 0.40
Warrants Issued	1,000,000
Maz Partners LP [Member] | Subscription Agreement [Member] | Class A warrant [Member]
Date of Issuance	Mar. 31, 2016
Warrant Exercise Price	$ 0.40
Warrants Issued	200,000
Maz Partners LP [Member] | Subscription Agreement [Member] | Class B warrant [Member]
Date of Issuance	Mar. 31, 2016
Warrant Exercise Price	$ 0.40
Warrants Issued
Chi Squared Capital Inc [Member] | Subscription Agreement [Member] | Class A warrant [Member]
Date of Issuance	May 30, 2016
Warrant Exercise Price	$ 0.40
Warrants Issued	100,000
Chi Squared Capital Inc [Member] | Subscription Agreement [Member] | Class B warrant [Member]
Date of Issuance	May 30, 2016
Warrant Exercise Price	$ 0.40
Warrants Issued	100,000
Firstfire Global Opportunities Fund LLC [Member] | Subscription Agreement [Member] | Class A warrant [Member]
Date of Issuance	Jul. 7, 2016
Warrant Exercise Price	$ 0.40
Warrants Issued	250,000
Firstfire Global Opportunities Fund LLC [Member] | Subscription Agreement [Member] | Class B warrant [Member]
Date of Issuance	Jul. 7, 2016
Warrant Exercise Price	$ 0.40
Warrants Issued	250,000
Guy Shalom [Member] | Subscription Agreement [Member] | Class A warrant [Member]
Date of Issuance	Oct. 11, 2016
Warrant Exercise Price	$ 0.40
Warrants Issued	119,000
Guy Shalom [Member] | Subscription Agreement [Member] | Class B warrant [Member]
Date of Issuance	Oct. 11, 2016
Warrant Exercise Price	$ 0.40
Warrants Issued

Stockholders' Equity - Summar35

Stockholders' Equity - Summary of Stock Option Activity (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Equity [Abstract]
Amount of options, Outstanding at beginning of year	561,280
Amount of options, Granted	5,440,483	592,000
Amount of options, Exercised	(697,086)
Amount of options, Cancelled	(550,000)	(30,720)
Amount of options, Outstanding at the end of year	4,193,397	561,280
Amount of options, Vested and expected-to-vest at end of period	3,288,062	561,280
Weighted average exercise price, Outstanding at beginning of year	$ 0.0666
Weighted average exercise price, Granted	0.1336	0.06
Weighted average exercise price, Exercised
Weighted average exercise price, Cancelled	(0.3956)
Weighted average exercise price, Outstanding at the end of year	0.11	0.0666
Weighted average exercise price, Vested and expected-to-vest at end of period	$ 0.11	$ 0.06
Aggregate intrinsic value, Outstanding at the end of year	$ 1,006,415	$ 527,603
Aggregate intrinsic value, Vested and expected-to-vest at end of period	$ 789,134	$ 527,603

Stockholders' Equity - Schedu36

Stockholders' Equity - Schedule of Stock Options Outstanding Exercise Price Range (Details) - $ / shares		12 Months Ended
		Dec. 31, 2016	Dec. 31, 2015		Dec. 31, 2014
Stock options outstanding		4,193,397	561,280
Stock Options [Member]
Stock options outstanding		4,193,397	561,280
Weighted average remaining contractual life		9 years 3 months	8 years 9 months
Stock options exercisable		4,193,397	561,280
Exercise Price One [Member]
Exercise price		$ 0.4	$ 0.4
Stock options outstanding		1,208,600	78,720
Weighted average remaining contractual life		9 years 3 months	8 years 9 months
Stock options exercisable		1,208,600	78,720
Exercise Price Two [Member]
Exercise price		$ 0.2	$ 0.2
Stock options outstanding		1,870,000
Weighted average remaining contractual life		9 years	0 years
Stock options exercisable		1,870,000
Exercise Price Three [Member]
Exercise price	[1]
Stock options outstanding		1,114,797	482,560	[1]
Weighted average remaining contractual life	[1]	9 years 3 months	8 years 9 months
Stock options exercisable		1,114,797	482,560
[1]	Less than 1%

Stockholders' Equity - Schedu37

Stockholders' Equity - Schedule of Stock Options Outstanding Exercise Price Range (Details) (Parenthetical)	12 Months Ended
	Dec. 31, 2016
Equity [Abstract]
Stock option description	Less than 1%

Stockholders' Equity - Schedu38

Stockholders' Equity - Schedule of Fair value Assumptions (Details)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Equity [Abstract]
Expected volatility	157.00%	70.00%
Risk-free interest	0.69%	1.00%
Dividend yield	0.00%	0.00%
Expected life of up to (years)	6 years	6 years

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)

Oct. 03, 2016

Feb. 18, 2016

Nov. 17, 2015

Jul. 16, 2015

Jul. 14, 2015

Jul. 31, 2015

Dec. 31, 2016

Dec. 31, 2015

Sep. 30, 2015

Jul. 21, 2015

Jun. 29, 2015

Mar. 16, 2015

Mar. 15, 2015

Debt conversion of convertible of shares issued

274,719

Warrant exercise price per share

$ 0.80

Warrant term

24 months

Loss of settlement of debt

$ 678,027

Number of shares issued for service value

$ 2,263,302

$ 885,984

Stock price per share

$ 0.40

$ 0.40

$ 0.107

$ 0.40

$ 0.40

Stock options shares granted

5,440,483

592,000

Stock options exercise price per share

Stock options volatility

157.00%

70.00%

Total value of options

$ 35,668

2017 [Member]

Total value of options

16,485

2018 [Member]

Total value of options

12,364

Emerald Medical Applications Ltd [Member]

Loan payable

490,000

Lior Wayn [Member]

Accounts payable

$ 3,252

$ 3,480

Three Acting Directors [Member]

Number of shares issued for services

1,195,000

Number of shares issued for service value

$ 1,194,403

Stock price per share

$ 1

Chairman [Member]

Stock options shares granted

180,000

Fully vested stock option shares

$ 90,000

Number of stock option shares vested over periods

90,000

Stock options exercise price per share

$ 0.20

Stock options volatility

113.00%

Stock options discount rate

1.14%

Total value of options

$ 64,518

Share Exchange Agreement [Member] | Chief Executive Officer and Founder [Member]

Warrant exercise price per share

$ 0.0001

Number of common stock shares issued

5,474,545

Number of shares issued value

$ 877,380

Holders 5 [Member]

Debt principal amount

$ 87,910

Debt conversion of convertible of shares issued

274,719

Debt conversion price per share

$ 0.32

Warrant exercise price per share

$ 0.80

Warrant term

24 months

Employee Payable (Details Narra

Employee Payable (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Monthly wages payable employee	$ 101,341	$ 29,092
Related Party [Member]
Monthly wages payable employee		3,480
Unrelated Party [Member]
Monthly wages payable employee		$ 25,612

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - Axel Springer Plug & Play Accelerator GmbH [Member] - USD ($)	Dec. 31, 2016	Dec. 31, 2015	Jul. 08, 2014
Convertible promissory note, amount			$ 29,719
Accrued interest	$ 2,013	$ 0

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative)	12 Months Ended
	Dec. 31, 2016USD ($)
Total grants received	$ 222,000
Sales [Member]
Royalty rate percentage	3.50%

Derivative Liabilities from C43

Derivative Liabilities from Convertible Notes - Axel Springer (Details Narrative)	Nov. 17, 2015	Dec. 31, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Fair value assumptions, expected volatility rate	149.00%	143.90%
Fair value inputs, probability percentages		100.00%

Derivative Liabilities from C44

Derivative Liabilities from Convertible Notes - Axel Springer - Schedule of Fair Value Measurement Reccurring Basis (Details) - Convertible Note [Member] - Level 3 [Member]	12 Months Ended
	Dec. 31, 2015USD ($)
Derivative liabilities , Beginning Balance	$ 20,532
New Issuances, Derivative liabilities
Extinguishment, Derivative liabilities	(20,532)
Change in Fair Value, Derivative liabilities
Derivative liabilities, Ending Balance

Other Receivables (Details Narr

Other Receivables (Details Narrative) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Receivables [Abstract]
Other receivables	$ 9,356	$ 25,797

Accounts Payable and Accrued 46

Accounts Payable and Accrued Liabilities (Details Narrative) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Payables and Accruals [Abstract]
Accounts payable and accrued liabilities	$ 258,795	$ 90,705

Income Taxes (Details Narrative

Income Taxes (Details Narrative)	12 Months Ended
	Dec. 31, 2016USD ($)
Israeli [Member]
Net operating loss carry forwards	$ 2,484,835
Israeli [Member] | 2015 [Member]
Corporate tax rate	26.50%
Israeli [Member] | 2016 [Member]
Corporate tax rate	25.00%
Israeli [Member] | 2017 [Member]
Corporate tax rate	24.00%
Israeli [Member] | 2018 [Member]
Corporate tax rate	23.00%
U.S[Member]
Net operating loss carry forwards	$ 14,670,241
Net operating losses expiration period	2,035

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Net loss carry-forward	$ 17,155,076	$ 471,980
Total deferred tax assets	5,730,945	125,075
Valuation allowance	(5,730,945)	(125,075)
Net deferred tax assets

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - Subsequent Event [Member]	Feb. 24, 2017$ / sharesshares	Jan. 26, 2017shares	Jul. 07, 2016USD ($)	Jul. 07, 2016EUR (€)	Dec. 31, 2016shares
Subscription Agreement [Member] | Restricted Stock [Member]
Number of common stock issued, shares	1,315,563
Subscription price per share | $ / shares	$ 0.40
Viva Technology Paris [Member]
First prize at the inaugural edition | $			$ 526,000
Viva Technology Paris [Member] | EUR [Member]
First prize at the inaugural edition | €				€ 500,000
Lior Wayn [Member]
Number of common stock issued, shares		5,212,878
Alimi Ahmed [Member] | Class E Warrants [Member]
Number of common stock issued, shares		900,000
Mr. Wayn [Member] | Class E Warrants [Member]
Number of common stock issued, shares					1,700,000